
==== Front
Virol J
Virol J
Virology Journal
1743-422X
BioMed Central London

39180020
2470
10.1186/s12985-024-02470-3
Review
From discovery to treatment: tracing the path of hepatitis E virus
Letafati Arash arashletafati@yahoo.com

12
Taghiabadi Zahra 2
Roushanzamir Mahshid 23
Memarpour Bahar 24
Seyedi Saba 2
Farahani Ali Vasheghani 2
Norouzi Masoomeh 2
Karamian Saeideh 2
Zebardast Arghavan 2
Mehrabinia Marzieh 2
Ardekani Omid Salahi 2
Fallah Tina 2
Khazry Fatemeh 2
Daneshvar Samin Fathi 2
Norouzi Mehdi 12
1 https://ror.org/01c4pz451 grid.411705.6 0000 0001 0166 0922 Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 grid.411705.6 0000 0001 0166 0922 Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran
3 https://ror.org/00wjc7c48 grid.4708.b 0000 0004 1757 2822 Department of Pharmacological and Biomolecular Science, University of Milan, Milan, Italy
4 https://ror.org/01k3mbs15 grid.412504.6 0000 0004 0612 5699 Shahid Chamran University of Ahvaz, Ahvaz, Iran
23 8 2024
23 8 2024
2024
21 1945 5 2024
14 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
The hepatitis E virus (HEV) is a major cause of acute viral hepatitis worldwide. HEV is classified into eight genotypes, labeled HEV-1 through HEV-8. Genotypes 1 and 2 exclusively infect humans, while genotypes 3, 4, and 7 can infect both humans and animals. In contrast, genotypes 5, 6, and 8 are restricted to infecting animals. While most individuals with a strong immune system experience a self-limiting infection, those who are immunosuppressed may develop chronic hepatitis. Pregnant women are particularly vulnerable to severe illness and mortality due to HEV infection. In addition to liver-related complications, HEV can also cause extrahepatic manifestations, including neurological disorders. The immune response is vital in determining the outcome of HEV infection. Deficiencies in T cells, NK cells, and antibody responses are linked to poor prognosis. Interestingly, HEV itself contains microRNAs that regulate its replication and modify the host’s antiviral response. Diagnosis of HEV infection involves the detection of HEV RNA and anti-HEV IgM/IgG antibodies. Supportive care is the mainstay of treatment for acute infection, while chronic HEV infection may be cleared with the use of ribavirin and pegylated interferon. Prevention remains the best approach against HEV, focusing on sanitation infrastructure improvements and vaccination, with one vaccine already licensed in China. This comprehensive review provides insights into the spread, genotypes, prevalence, and clinical effects of HEV. Furthermore, it emphasizes the need for further research and attention to HEV, particularly in cases of acute hepatitis, especially among solid-organ transplant recipients.

Keywords

HEV
Prevalence
Transmission
Pathogenesis
Treatment
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

As an enteric RNA virus, HEV can cause both disease outbreaks and sporadic cases. This virus belongs to the Hepeviridae family and is characterized as a single-stranded, positive-sense RNA virus. Contamination of the water supply is the main cause of virus outbreaks, although there are evidence suggests that the virus may also spread through person-to-person transmission. After a significant hepatitis outbreak in Kashmir in 1978, it was initially established as a distinct infectious agent. The virus was subsequently found in the fecal specimens of Soviet military recruits posted in Afghanistan in 1981 [1–3]. Human-infecting HEV genotypes can be found in the species Paslahepevirus balayani and Rocahepevirus ratti [4]. HEV consists of two major species: mammalian HEV, which leads to acute hepatitis in humans and is harbored by pigs and possibly other animals, and avian HEV, accountable for a condition known as big liver and spleen disease in chickens [5, 6]. HEV RNA becomes detectable in blood and stool roughly three weeks after infection. Viremia typically persists for three to six weeks, while the virus continues to be shed in stool for about four to six weeks [7]. Typically, the incubation period of HEV infection ranges from 2 to 6 weeks [8]. Increasing age and living in low socioeconomic conditions are contributing risk factors for HEV infection [9].

A comprehensive study estimated the worldwide anti-HEV IgG seroprevalence at 12.47%, the pooled anti-HEV IgM seroprevalence at 1.47%, and the pooled prevalence of HEV RNA-positive in the general population at 0.20% [10]. In the overall population, the mortality rate varies from 0.5 to 4%. However, for pregnant women infected with HEV, the mortality rate escalates to as high as 30% [11]. In immunocompromised individuals, this infection can potentially become a chronic and significant medical issue, particularly for those who have undergone solid organ transplants as well as for patients with HIV, leukemia, and lymphoma [12]. According to a systematic review and meta-analysis, the prevalence of HEV infection among organ transplant recipients ranges from 6 to 29.6%, while among HIV-positive patients, it ranges from 3.5 to 19.4% [13]. The occurrence of HEV infection differs across various global regions, primarily due to distinct genotypes [14]. HEV has eight different genotypes, but only five of them are linked to human diseases and are designated as HEV-1 through HEV-4 and HEV-7 [15]. HEV-1 and HEV-2 are prevalent in developing nations like those in Africa, Asia, and Mexico, while HEV-3 and HEV-4 are more prevalent in developed countries. Genotypes 1 and 2 are typically linked to human infection, often resulting in outbreaks in regions with inadequate sanitation. Genotypes 3 and 4 are typically transmitted through consuming undercooked meat or potentially via contact with infected animals. HEV strains originating from animals such as rabbits, pigs, camels, and rats possess zoonotic potential [16, 17]. In endemic region, HEV primarily transferred via the fecal-oral route, often via the pollution of drinking water [5]. Other modes of transmission, such as contaminated food, maternal-fetal (vertical transmission), and modes involving injection, are less frequent [18]. Remarkably, the age-specific seroprevalence patterns of HEV differ significantly from those of HAV, despite both viruses sharing similar transmission routes in regions where these diseases are prevalent [19].

This comprehensive review explores the complexities of mammalian HEV, highlighting its transmission routes, various genotypes, global prevalence patterns, and the range of clinical manifestations it can cause. Emphasizing the critical need for expanded research efforts, particularly in the domain of acute hepatitis, the text underscores the importance of heightened scrutiny, especially within vulnerable populations such as recipients of solid-organ transplants. By deepening our understanding of these aspects, we aim to pave the way for more effective strategies for the management and prevention of this infectious pathogen.

Evolutionary history

In 2000, phylogenetic studies on four different HEV strains and a re-evaluation of conserved regions in the capsid, helicase, and polymerase showed that HEV should not be classified in the Caliciviridae family. Instead, it was repositioned into an unassigned clade with an uncertain taxonomic status, although it exhibited a closer relationship to the Togaviridae family [20]. Within the “alpha-like” major groupings, this ultimately clarified the virus’s classification, resolving its placement within both the “Picorna-like” upper-level groupings and the “alpha-like” supergroup. With the increasing availability of sequences, it became increasingly evident that HEV was significantly differentiated from various viral genera and lineages. Consequently, it was designated as its genus (Hepevirus) by 2004 and later as its distinct family (Hepeviridae) in 2009 [21, 22]. In 2014, the classification of Hepeviridae underwent a reassessment, resulting in the creation of two new genera: Orthohepevirus and Piscihepevirus [23] (Fig. 1).

Fig. 1 A timeline chronology of key advancements in the field of hepatitis E virus [6, 177–184]

Capsid proteins of the hepatitis virus are crucial for its classification, serving as key distinguishing features [24]. Despite an in-depth examination of the non-structural protein-encoding region, the source of the HEV capsid remained inconclusive, as the Benyviridae family comprises non-enveloped rod-shaped plant viruses, while HEV capsids exhibit a T = 3 icosahedral structure, comprise approximately 180 copies of the capsid protein [25, 26]. Icosahedral capsids are characterized by a triangulation number such as T1, T3, T4, etc., indicating identical equilateral triangles constructed by subunits [27]. Surprisingly, it wasn’t until 2011 that it was discovered that the HEV capsid protein had its closest structural resemblance to capsids found in members of the Astroviridae family, which infect vertebrates [28]. Astroviruses, akin to HEV, possess a T = 3 icosahedral capsid structure. However, they are affiliated with the “Picorna-like” supergroup of viruses. Presently, the enigma of HEV’s origin persists, as the non-structural protein-encoding region is categorized within the “alpha-like” supergroup, as opposed to the structural region [25].

HEV’s taxonomy

HEV belongs to the family Hepeviridae, which is categorized into two main subfamilies: Orthohepevirinae (encompassing four genera) and Parahepevirinae (only one genus: Piscihepevirus) based on international committee on taxonomy of viruses (ICTV) report in 2022 [29, 30]. Whitin the Orthohepevirinae subfamily, genera Paslahepevirus and Rocahepevirus can infect humans, wild and domestic mammals, while Chirohepevirus affects bats and Avihepevirus infects birds [30]. Paslahepevirus includes two species: P. balayani and P. alci (specific to moose). P. balayani, formerly known as Orthohepevirus A, infects humans and various mammals. It has 8 distinct genotypes, with genotypes 1–4 causing significant human disease. Genotypes 1 and 2 lead to large epidemics in developing countries, while zoonotic infections with genotypes 3 and 4 cause sporadic and clustered cases of HEV [31, 32].

Virion structure and genome organization

HEV has a genome consisting of positive-sense, single-stranded RNA, approximately 7.2 kb in size. This RNA genome features a 7-methylguanosine RNA cap at the 5′ terminus and a polyadenylated tail at the 3′ end [33]. The viral genetic material usually contains three open reading frames (ORFs), specifically known as ORF1, ORF2, and ORF3. However, a fourth ORF (ORF4), which can be found in ORF1, is exclusive to genotype 1 (G-1 HEV) strains and ORF4-specific antibodies are present in G-1 HEV case serum [34]. ORF1 extends about 5 kb in length and is located at the 5′ end of the genome, while ORF2 is around 2 kb and is positioned at the 3′ end. Notably ORF3 consists of 372 bases, with its 5′ end sharing an overlap of merely 4 nucleotides with ORF1 and its 3′ end overlapping with ORF2 by 331 nucleotides [35, 36]. As well, ORF1 represents a substantial polyprotein harboring numerous functional domains crucial for virus replication. On the contrary, ORF2 and ORF3 originate from a 2.2 sub-genomic RNA generated during virus replication, fulfilling functions in virus assembly and egress, respectively [37]. In HEV-infected cells, the quantity of sub-genomic RNA copies is notably greater than that of their genomic RNA equivalents [37] (Fig. 2). ORF2 is crucial for HEV assembly, facilitating the packaging and folding of viral RNA and the formation of viral particles. Strategies include disrupting ORF2’s binding to RNA elements at the 5′ end of the genomic RNA and targeting ORF2 oligomerization to form the capsid, both of which could be hopeful approaches for antiviral drug development. Alternatively, ORF3 facilitates viral particle release by connecting assembled particles to the ESCRT (endosomal sorting complexes required for transport) pathway through its attachment to the ESCRT component Tsg101 (tumor susceptibility gene 101) [38]. Furthermore, the ORF4 protein interacts with viral helicase, RNA-dependent RNA polymerase (RdRp), X, eukaryotic elongation factor 1 isoform-1 (eEF1α1), and tubulinβ, forming a protein complex. ORF4 and eEF1α1 together boost viral RdRp activity. In addition, it was reported that a proteasome-resistant ORF4 mutant greatly increased HEV replication [34].

Fig. 2 Hepatitis E virus genome: The genome organization of the Hepatitis E Virus (HEV) involves a single-stranded positive-sense RNA molecule, approximately 7.2 kilobases in length. At its 5’ end, the RNA molecule begins with a 7-methylguanosine RNA cap, while at the 3’ terminus, it is polyadenylated. Notably, the HEV genome consists of three consistently conserved open reading frames (ORFs) present in all identified HEV strains: ORF1, ORF2, and ORF3. ORF1 is responsible for encoding nonstructural polyproteins, which contain various functional domains including methyltransferase (Met), X domain, helicase (Hel), hypervariable region (HVR), RNA-dependent RNA polymerase (RdRp), Y domain, and papain-like cysteine protease (PCP). ORF2 encodes the structural capsid protein, which comprises P, S, and M domains. The capsid protein is essential for viral assembly and its interaction with the immune system of the host. ORF3 contains a highly conserved PxxP motif and encodes a small protein that has been demonstrated in vitro to bind with various proteins involved in cellular signal transduction [185–194]

Epidemiology

Five genotypes of HEV have been identified that can cause harm. Among these genotypes, genotype 1 and genotype 2 exclusively affect humans. Genotype 3 and genotype 4 are associated with animal reservoirs, specifically found in wild boars, deer, swine, and rabbits [39, 40]. Recently, a new genotype, genotype 7, has been discovered, which is primarily found in camels. There has been a documented case of human infection with this genotype, involving an individual who owned camels and had previously undergone a liver transplant in the United Arab Emirates [41]. Genotype 1 strains of HEV have been identified in various regions, including China, Pakistan, Nepal, the Indian subcontinent, Afghanistan, Bangladesh, and several sub-Saharan African countries. In contrast, genotype 2 strains are prevalent in the Central African Republic, Chad, Nigeria, Mexico, and Sudan. Genotype 3 strains have been found in Central and Southern Japan, as well as in the United States, other North American countries, Europe, Australia, and New Zealand. Moreover, genotype 4 is known to exist in northern Japan, China, India, and several European countries, including France and Germany. It is important to note that genotype 7 has only been detected in the United Arab Emirates, and there is limited research available regarding its geographic distribution [42, 43].

HEV genotype 1 strain-induced outbreaks are commonly associated with the transmission of the virus through contaminated water sources. India has experienced recurring outbreaks since the initial outbreak in Delhi in 1955. These outbreaks have affected hundreds or even thousands of individuals, demonstrating a significant impact observed during the period from 1975 to 1994 [42]. This outbreak affected over 200 villages with a total population of 600,000. It resulted in 20,083 cases of jaundice and 600 deaths within a seven-week period. Pregnant women, in all three trimesters, were more frequently infected with HEV compared to men and non-pregnant women aged 15–45 years [18, 44]. Another significant epidemic occurred between 1986 and 1988, leaving a lasting impact on the affected region. During this period, there were approximately 120,000 reported cases of HEV infection. This epidemic claimed the lives of 765 individuals, with 51 of them being pregnant women [42]. The most extensive outbreak of HEV in India occurred from December 1990 to April 1991 in Kanpur. This outbreak had a significant impact, with a staggering 79,000 reported cases of clinical hepatitis [45]. Indeed, HEV outbreaks have been documented in various Asian countries, including Uzbekistan, Indonesia, Japan, Vietnam, Iraq, Pakistan, Bangladesh, Nepal, Myanmar, China, and Turkmenistan [46].

Moreover, in the United States, individuals of African descent seem to have a reduced occurrence of HEV infection. Data from the national health and nutrition examination survey (NHANES) indicate that the prevalence of anti-HEV IgG was 14.5% among non-Hispanic blacks, 22.1% among non-Hispanic whites, and 20.3% among Mexican-Americans [47]. In non-Hispanic black individuals, research has shown that the presence of specific gene polymorphisms within the apolipoprotein E gene (APOE) is associated with lower anti-HEV IgG seroprevalence. The APOE gene plays a role in regulating lipoprotein metabolism. Among individuals with these gene polymorphisms, specifically the APOE ε4 allele, there was significantly lower seropositivity for HEV compared to those with the APOE ε2 allele [48]. In South Africa, where genotype 1 of the virus has persisted, the occurrence of anti-HEV IgG was discovered to be less common among black blood donors when compared to white or mixed-race donors. This disparity suggests that there may be variations in HEV exposure and immune responses among different racial and ethnic groups in South Africa [49].

Transmission

HEV causes widespread outbreaks of viral hepatitis transmitted through contaminated water and is the leading cause of sporadic cases of acute hepatitis and severe liver failure in these regions [50]. Transmission to humans from various species, including pigs, rabbits, deer, camels, and rats, has been well-documented for HEV strains. This typically occurs by eating raw or undercooked meat from infected animals or through direct contact with infected animals [51].

HEV is predominantly spread by the fecal-oral pathway [50]. Epidemics have a shared point of origin when the epidemic curve is markedly condensed, usually spanning approximately six to eight weeks due to contamination [18]. Studies have demonstrated that localities that consume different water supplies for drinking, particularly safeguarded well water, both before and during epidemics, do not experience the disease [18]. Epidemics can stem from the pollution of river water utilized for drinking, sewage disposal, washing, and bathing. Typically, outbreaks in these environments tend to happen in the winter months when water levels drop, leading to a rise in water contamination due to higher concentrations of contaminants [50]. Groundwater, crops, and waterways can all be subject to contamination. The act of openly in backyards and open fields can act as an extra origin of fecal pollution for groundwater, crops, and water bodies [18, 52].

The transmission route of sporadic diseases triggered by HEV-1 and HEV-2 is also currently being studied [18]. The transmission of sporadic HEV infection within families was a rare incidence. Human infections are typically contracted through three primary pathways: direct contact with infected animals, zoonotic foodborne consumption, and environmental contamination caused by the runoff of animal waste. The spread of HEV-3 and HEV-4 via food-borne zoonotic routes has also been proposed [53]. Wild boars, sika deer, and domestic pigs play a part in the cross-infection of HEV [4]. Consuming partially cooked flesh or liver (considered a culinary delicacy in numerous nations) might be the cause of autochthonous (locally acquired) cases and outbreaks of HEV [54]. A commonly observed method of HEV transmission is the consumption of raw liver from grocery stores or Corsican figatelli sausage in Europe [55]. These livers and sausages frequently contain live HEV. Work-related contact with domestic pig farms, manure, and sewage is a notable risk for HEV infections in multiple regions [56–59]. It was reported that swine veterinarians had a 1.9 times higher likelihood of being seropositive for HEV compared to non-swine veterinarians [60]. Additionally, environmental contamination can result from pig slurry through various routes. Employing pig slurry as fertilizer for pastures can result in the contamination of agricultural produce such as raspberries, strawberries, and various vegetables commonly used in salads [61, 62]. Run-off from outdoor pig farms can contaminate coastal waters [63, 64], affecting marine life, such as fish and shellfish [65].

Tropism

Despite its main focus on the liver, HEV has exhibited the ability to replicate in various tissues, resulting in extrahepatic effects like neurological symptoms, myositis, renal and hematologic complications in HEV-infected individuals [66, 67]. Through experimental infections of animals with HEV, researchers have detected negative-strand viral RNA, a sign of continuous viral reproduction. This replication isn’t limited to the liver; it is also present in the pig’s intestinal tract, colon, and lymph nodes [68]. Similarly, rabbit models have shown negative-strand RNA intermediates in the liver, kidney, small intestine, spleen, and stomach [69].

As well, patients with HEV, whether in acute or chronic cases have presented neurological manifestations, yet the actual prevalence and the underlying pathogenic mechanisms are not definitively established [8]. Given that HEV is disseminated through the fecal-oral transmission route, it is most probable that the primary site for the virus’s initial replication is the gastrointestinal system. From there, the virus can infiltrate the bloodstream and impact other organs [70, 71]. Furthermore, the association between HEV and kidney disorders is indicated by renal complications [72, 73]. The recent confirmation of this link is based on the discovery of HEV in urine samples from individuals with both acute and chronic virus infections, as well as in monkeys. Furthermore, immunohistochemical evidence has revealed the existence of afflicted cells within the kidneys of these animals [74].

Overall, although HEV is primarily associated with liver infections, its ability to replicate in various tissues highlights its broader impact on human health. Ongoing research into the prevalence and mechanisms of these complications is crucial for developing targeted interventions and improving patient outcomes.

Clinical features

The clinical features of HEV infection resemble those of other hepatitis viruses and include a broad spectrum of symptoms. The prevailing form of illness is acute icteric hepatitis, usually commencing with several days of flu-like symptoms, such as fever, chills, abdominal discomfort, loss of appetite, queasiness, emesis, and diarrhea. Additional symptoms may encompass pale or clay-colored stools, darkened urine, joint pain, asthenia, and a temporary macular skin rash. Subsequently, these initial symptoms are succeeded by the development of jaundice, marked by the darkening of urine and lightening of stool color. Itchiness may also manifest. Fever and other preliminary symptoms typically wane quickly once jaundice sets in [75]. At times, HEV infection can manifest entirely without symptoms and go unnoticed. The precise frequencies of asymptomatic infection and anicteric hepatitis remain unknown but are thought to be more common than icteric disease [75–77]. Laboratory tests reveal elevated levels of bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, and alkaline phosphatase [78]. Serum aminotransferase and bilirubin levels typically commence their normalization within 6 weeks [77].

A minority of patients may encounter severe variants of the condition, including fulminant or subacute hepatic failure [77]. Pregnant women, particularly those in the second and third trimesters, are more susceptible to the virus during outbreaks and have a higher risk of complications. Additionally, HEV-infected pregnant women may witness a greater incidence of miscarriages, stillbirths, and deaths among newborns [79–83]. Severe liver damage can result in sub-massive or massive necrosis, causing the collapse of liver tissue [75, 79, 84, 85].

Other complications associated with HEV

Hepatitis E infection has been linked to a diverse range of extra-hepatic manifestations, primarily affecting the neurological, renal, cardiac, and hematological systems [86] (Fig. 3). Neurological manifestations, increasingly recognized as complications of HEV infection, are the most frequent extrahepatic symptoms. Multiple neurological disorders have been reported in Europe (74%) and the Southeast Asia Region (SEAR), particularly in Bangladesh, India, and France (15%). Guillain-Barré syndrome (37%) and Neuralgic amyotrophy (39%) are the most common neurological conditions linked to HEV infection [87]. According to the systematic review by Rawla et al., neuralgic amyotrophy was observed in 102 out of 179 patients (56.98%), while Guillain-Barré syndrome was present in 36 out of 179 patients (20.11%) [88]. One patient was diagnosed with myasthenia gravis, and two others had poly-neuromyopathy. Additionally, six patients experienced mononeuritis multiplex, while five suffered from meningo-radiculitis and cerebral ischemia. Transverse myelitis was found in one patient, peripheral neuropathy in three patients, and vestibular neuritis in one patient. Lastly, one patient was affected by myositis [88]. According to the results of case report experiment, a renal transplant recipient experienced encephalopathy, unsteady walking, Lhermitte’s sign, difficulty emptying the bladder, and peripheral sensory nerve damage as a result of long-term HEV infection [89]. These findings highlight the potential involvement of the nervous and musculoskeletal systems in HEV infections, emphasizing the need for healthcare professionals to be vigilant in recognizing and monitoring these disorders in infected patients for appropriate management and treatment.

Fig. 3 The extra-hepatic manifestations of HEV infection can be depicted as follows: HEV is associated with myocarditis and acute pancreatitis, affecting the heart and pancreas respectively. Neurological and hematological symptoms include Guillain-Barré syndrome, Bell’s palsy, neuralgic amyotrophy, thrombocytopenia, hemolytic anemia, and aplastic anemia. Additionally, skeletal-related manifestations of HEV infection can result in polyarthritis [73, 79, 86, 90, 93, 195–208]

A study was conducted to report the extra-hepatic manifestations of hepatitis E virus through a retrospective review of data from 106 cases of autochthonous hepatitis E (105 acute and 1 chronic) [90]. Eight cases (7.5%) presented with neurological syndromes, including brachial neuritis, Guillain-Barré syndrome, peripheral neuropathy, neuromyopathy, and vestibular neuritis. One patient had a cardiac arrhythmia, twelve patients (11.3%) had thrombocytopenia, fourteen (13.2%) had lymphocytosis, and eight (7.5%) had lymphopenia, none of which had any clinical consequences. Moreover, monoclonal gammopathy was documented in seventeen cases (26%) [90].

Additionally, in other studies, a 32-year-old male with acute HEV infection was reported to have leukocytosis [91]. Another case involved a 48-year-old male who experienced massive hemolysis, leading to renal failure, also associated with acute HEV infection [92]. Long QT syndrome (LQTS) and Torsades de Pointe (TdPe) (a specific type of ventricular tachycardia( were observed in one case involving a 62-year-old woman with acute HEV infection [93]. The observation of this unusual case highlights the importance of our awareness and understanding of the mechanisms behind LQTS, which will aid in identifying at-risk patients and minimizing their exposure to risk factors.

The occurrence of acute pancreatitis due to HEV infection is uncommon. Somani et al. describe a case where severe acute pancreatitis developed in a 35-year-old man with jaundice lasting one week. His serum tested positive for IgM anti-HEV and negative for hepatitis A, B, and C viruses. Despite undergoing hemodialysis and blood transfusion, the patient experienced refractory hypotension and did not respond to inotropic medications. His condition rapidly deteriorated, leading to a fatal outcome. This case illustrates that hepatitis E virus infection can lead to severe acute pancreatitis accompanied by multiorgan failure [94].

These results indicate that a range of extra-hepatic manifestations can occur with hepatitis E. However, it’s important to mention that most of these disorders were observed in isolated cases or limited numbers of patients. Further investigations are needed to enhance our knowledge of the pathogenesis, clinical characteristics, and optimal management strategies for HEV-related digestive system disorders.

Vulnerability to HEV infection

Susceptibility to HEV infection is influenced by various factors. In nations where the disease is widespread and where transmission primarily occurs through the fecal/oral route, the availability of safe public water supplies and effective waste management systems is essential [95]. While race does not appear to influence HEV infection, there is a notable geographical bias [96]. Tropical and subtropical countries with poor socioeconomic and hygienic conditions are more prone to HEV outbreaks. Asia, Africa, and Mexico have experienced epidemics, while Latin America, industrialized areas, and certain European countries have not reported outbreaks except for Mexico [97–101]. Bolivia, Chile, Cuba, and Mexico have endemic HEV [96]. Second, a sex-related bias is observed in HEV infection, with males being at higher risk of developing clinical hepatitis in contrast to females [96]. The gender distribution among adults varies from an equal 1:1 ratio to a 3:1 ratio, favoring males [96]. The causes for this bias are not well understood, but they may be linked to occupational and social roles. However, children with clinical HEV do not show a sex bias [96, 99].

Third, age is a factor in HEV infection rates and clinical disease. During HEV epidemics, individuals aged 15 to 40 have the highest infection and clinical disease rates. Children generally have lower infection rates and are less likely to be affected by clinical HEV compared to adults [102, 103]. Studies in India and Vietnam indicate that children under 10 have a lower prevalence of HEV, although acute HEV can still occur in children, albeit rarely [96].

Fourth, pregnant women are especially at risk of developing severe illness if they contract HEV. Pregnant women affected by HEV displayed pooled Case Fatality Rates (CFRs) of 20.8% [104]. Pregnant women infected with the virus are at a higher risk of developing fulminant hepatic failure (FHF) and experiencing adverse outcomes such as abortion, premature delivery, or neonatal death. Several factors contribute to the heightened susceptibility and seriousness of HEV infection among pregnant women [80].

Hormonal and immunological changes throughout pregnancy could influence the seriousness of HEV infection, even though there is a lack of supporting data. Limited access to adequate medical care and nutrition in developing countries further contributes to higher maternal morbidity and mortality associated with HEV [105]. The compromised immune system of pregnant women, combined with factors like malaria, parasitic infections, and other viral and bacterial infections that are widespread in developing countries, weaken their immune response, making them more susceptible to HEV infection [105, 106]. Therefore, those who live in tropical and subtropical areas with poor socioeconomic and hygienic circumstances, as well as men, people in their 15–40 s, and pregnant women are susceptible to HEV infection [96].

Immune responses

HEV infection can become chronic in immunocompromised cases (e.g. HIV cases, recipients of organ transplants, hematologic malignant conditions) [107–109]. Studies show reduced CD2, CD3, and CD4 lymphocytes in transplant recipients who develop chronic HEV compared to those who resolve the infection [107]. This suggests that compromised T-cell responses in immunocompromised individuals can hinder the elimination of the virus, leading to a persistent HEV infection [110]. Research have shown that it is the immune response, as opposed to direct harm to hepatocytes by the virus, that likely underlies the expression of HEV symptoms, such as self-limiting acute viral hepatitis (AVH) and acute liver failure (ALF) [111]. The concurrent appearance of icteric symptoms, an increase in antibodies, and a reduction in viral load support this idea [112]. In a study on HEV-induced acute hepatitis, elevated levels of anti-HEV IgM and IgG antibodies discovered. Individuals experiencing liver failure showed increased levels of gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin-2 (IL-2), and IL-10 compared to those with self-limiting acute hepatitis. Remarkably, HEV RNA was present in cases of AVH but not in individuals with liver failure. Given that most ALF patients developed encephalopathy and underwent testing within a fortnight of symptom onset, and patients with AVH were sampled about 14 days after symptom onset, the absence of HEV RNA in liver failure cases is unlikely to be solely attributed to the time between disease onset and sampling. These findings suggest that both Th1- and Th2-type immune responses may contribute in the development of liver failure in symptomatic HEV patients [113].

NK and T-cells are crucial in the immune response to HEV infection. A study on acute HEV infection compared to healthy individuals, observed that HEV patients exhibited reduced percentages of CD3+/CD69+/IFN-γ and CD3+/CD69+/TNF-α, along with elevated proportions of CD4+ cells. Interestingly, the quantities of CD69+/IL-4 cells and CD8 + cells showed no significant difference between HEV patients and healthy individuals. It is suggested that the increase in CD4 + cells in patients may signal an augmentation in the population of NK cells [114]. A study on acute HEV patients revealed reduced proportions of NK and NKT cells among MCs in HEV patients compared to controls. However, there was a significantly higher proportion of activated NK cells in patients. The decrease in the total count of NK and NKT cells in PBMCs (peripheral blood mononuclear cells) could result from the specific accumulation or apoptosis of these cells in the livers of infected individuals. It is suggested that the decreased presence of NK cells in pregnant women may contribute to their increased vulnerability to severe HEV, as it diminishes their capacity to eliminate the virus from the liver [115].

The proliferation of CD4 + T cells producing IFN- γ and TNF-α in HEV patients also contributes to restricting HEV replication and assisting in the resolution of the infection. The increase in disease severity has an inverse correlation with the expansion of T cells producing cytokines specific to the antigen. Individuals experiencing disease exhibited diminished proliferation of CD4 + T cells when stimulated by pORF3, leading to decreased levels of IFN-γ and TNF-α production in contrast to those with mild disease. As these cytokines are recognized for their role in regulating viral replication, the absence of an increase in HEV-specific T cells producing cytokines in patients with fulminant HEV might lead to immune system failure in controlling HEV replication, resulting in more extensive liver injury. Recent research has supported this idea, as it reveals higher levels of HEV-RNA in the bloodstream of patients with fulminant HEV, in contrast to individuals with uncomplicated disease [116]. TNF-α not only contributes to hepatocyte death but also plays a role in liver tissue regeneration. Studies have shown that the TNF-α-mediated nuclear factor (NF)-kB pathway plays a role in the process of liver regeneration, a vital process for recovering liver function post-injury. As a result, a less robust TNF-α reaction in fulminant HEV might obstruct the recovery procedure [117–119].

Most patients become anti-HEV IgG positive over time, but the duration of IgG persistence remains unknown due to variations in sensitivity among different enzyme-linked immunosorbent assay (ELISA) assays. Nevertheless, in India, anti-HEV IgG can be identified for a minimum of 14 years after the outbreak [120]. Patients with uncomplicated HEV had a higher anti-HEV IgG-secreting cells compared to healthy controls [119]. The count of these cells was notably greater in individuals with fulminant HEV when compared to those with uncomplicated disease. B cells producing antigen-specific IgG were assessed by stimulating PBMCs with polyclonal agents. These findings represent the complete population of HEV-specific memory B cells, offering an indirect indication of antigen-specific IgG levels after HEV exposure. The link between memory B-cells and illness severity suggests these cells and anti-HEV antibodies may cause liver damage in HEV cases [119].

MicroRNA (miRNAs)

With a high degree of conservation, microRNAs (miRNAs) are classified as small non-coding RNAs and make up approximately 1% of the human genome. They possess the capacity to interact with approximately 60% of messenger RNAs (mRNAs) [121]. Besides viral transcripts, HEV is also capable of producing diverse miRNAs. The investigation of these miRNAs has predominantly hinged on predictive models, which are then confirmed through experimental validation using either in vivo or in vitro infection models. The lack of a suitable infectious model for HEV, characterized by slow replication in cell-cultured systems, has been a significant challenge in this research [122]. Nine potential HEV-miRNAs for HEV-1 have been revealed through predictive computational modeling, known as HEV-MD1, -MD2, -MD3, -MD31, -MD35, -MD39, -MR9, -MR10 and, -MR25 [123]. It has been proposed that the potential target sites for these HEV-miRNAs can be found at both the 3’-end and 5’-end of human mRNA. It is predicted that these HEV-miRNAs will specifically interact with genes involved in lipid and nitrogen metabolism, transmembrane transport, cellular differentiation, membrane organization, chromosome organization, and cell-cell signaling [123]. HEV is present in a state where it is enveloped within the liquid above cell cultures that are infected, as well as in the blood of individuals who have acute HEV infection. This finding implies that the virus might utilize these miRNAs to facilitate the process of envelopment and dissemination of its offspring within the host [26]. For instance, there have been forecasts suggesting that HEV-MD2 plays a role in controlling the synthesis of cyclin G-associated kinase (GAK), a pivotal element in clathrin trafficking and receptor signaling [123, 124].

Until now, the primary miRNAs that have been thoroughly studied for their impact on HEV replication are miR-122 and miR-214 [125, 126]. The gene encoding miR-122 is located on chromosome 18 within the human genome [127]. The miRNA identified as the most abundant in the human liver has been extensively studied for its involvement in cholesterol metabolism, liver cell differentiation, and the development of liver diseases such as hepatocellular carcinoma triggered by HCV and HBV [128, 129]. The interaction between miRNA-122 and the virus has a significant impact on viral replication. Specifically, the direct complementarity between miRNA-122 and a specific binding site on the viral genome, usually found in the RdRp region of the ORF1 gene, enhances viral replication [126]. Research has highlighted differences in the expression levels of certain miRNAs in HEV RNA-positive individuals when compared to negative blood donors. Specifically, these miRNAs include miR-1285, 151-3p, 302b, 526b, 520b, 627-5p, 628-3p, and 365 [130]. Furthermore, pregnant women with acute self-limiting HEV-1 infection exhibited a distinct expression pattern when compared to non-pregnant women. The presence of miR-188, 365a, 190b, 365b, 374c, 450a-1, 450b, 4482, 450a-2, 616, 2115, 580, 504, 3117, 4772, and 5690 was identified, enabling differentiation between acute infection, self-limiting acute infection, and acute liver failure [131](Table 1).

Table 1 MicroRNAs encoded by Hepatitis E Virus (HEV)

Name	Coding region	Binding site	Effects on host physiology	Identification method	Length
(nt)	Reference	
HEV-MD1	ORF1

(MeT domain)

	INCA1	Affects Cell Proliferation, Membrane Organization, and Transmembrane Transport	In silico (Computational Modeling)	22	[123, 132]	
HEV-MD2	ORF1

(MeT domain)

	GAK	Cellular component assembly, Vesicle-Mediated Transport, Alters Membrane Organization, Inhibits Production of Cyclin G-Associated Kinase	In silico (Computational Modeling)	22	[123, 132]	
HEV-MD3	ORF1

(Y domain)

	KDM4B	Affects Nitrogen Compound Metabolism, Alters Chromosome Organization	In silico (Computational Modeling)	22	[123, 132]	
HEV-MD31	ORF1

(RdRp domain)

	ADAMTS1 6	Cytoskeleton-dependent intracellular transport, Impairs Vesicle-Mediated Transport, Silences ADAMTS16 Gene Expression (can lead to fetal loss and pre-term labor)	In silico (Computational Modeling)	21	[123, 132]	
HEV-MD35	ORF1

(RdRp domain)

	CCDC34	Signal transduction	In silico (Computational Modeling)	22	[123, 132]	
HEV-MD39	ORF2	LRRC8A	Sulfur compound metabolism, Cell proliferation, Catabolism	In silico (Computational Modeling)	22	[123, 132]	
HEV-MR9	ORF1

(PCP domain)

	FKRP	Affects Cell Differentiation, Impairs Protein Maturation	In silico (Computational Modeling)	22	[123, 132]	
HEV-MR10	ORF1

(PCP domain)

	MMAB	Suppresses MMAB gene, Nitrogen compound metabolism, and Transmembrane Transport	In silico (Computational Modeling)	22	[123, 132]	
HEV-MR25	ORF1

(RdRp domain)

	PNPLA6	Affects Lipid Metabolism, Impairs Cell-Cell Signaling, Disrupts Transmembrane Transport	In silico (Computational Modeling)	21	[123, 132]	
HEV-miR-A26	ORF1

(MeT domain)

	IFN- β	Inhibits IFN-β generation	Animal Infection, Cell Transfection	22	[132]	

Diagnosis

HEV diagnosis is achievable using direct or indirect testing techniques. Direct diagnosis involves the measurement of HEV RNA in blood or stool samples, while indirect diagnosis is based on identifying the host’s immune response to HEV infection [73]. The diagnosis often involves employing nucleic acid amplification techniques (NATs) to analyze HEV RNA in biological specimens like stools, serum, and liver biopsy [133]. Direct methods identify viral particles, proteins, or nucleic acids in the samples by RT-PCR and immune-electron microscopy. Moreover, indirect tests have elevated sensitivity than anti-HEV IgM and IgG [134].

Optimal diagnosis of acute HEV infection is achieved by combining serological testing and NAT assays [135]. Indirect diagnosis involves the display of IgM and IgG anti-HEV antibodies in the serum using ELISA. The presence of IgM antibodies indicates acute infection and becoming detectable four days after jaundice begins [133]. Enzyme immunoassays rely on detection of anti-HEV antibodies or HEV capsid antigen. However, HEV antigen can remain for months after ribavirin clears HEV RNA, suggesting it doesn’t indicate infectious virions, thus its diagnostic role is unclear [3]. Anti-HEV IgM levels reach their peak at clinical presentation and remain relatively high for about 8 weeks, but subsequently decline rapidly. On the other hand, HEV IgG levels increase after the onset of symptoms, peak at approximately 4 weeks, and are retained at a high level for over a year [135].

The “gold standard” for confirming acute HEV infection is by identifying HEV RNA in biological samples like serum and feces [134, 135]. HEV RNA is detectable in fecal samples from the onset of symptoms and for up to six weeks thereafter, as well as in serum for four weeks from the start of the illness. Nevertheless, the accuracy of molecular tests for detecting HEV RNA depends on early patient presentation, timely sample collection, and appropriate transport and processing. Since viral RNA quantities may be minimal, and the timeframe for detecting HEV can be limited, the lack of detectable viral RNA does not necessarily indicate the absence of HEV infection [133, 136]. In most of the commercially accessible tests for detecting HEV RNA, the NAT technique is used. This technique comprises reverse transcriptase-polymerase chain reaction (RT-PCR), real-time PCR, and the loop-mediated isothermal amplification assay [137, 138].

In conclusion, the diagnosis of HEV involves a combination of direct and indirect testing methods. Direct tests detect HEV RNA, while indirect tests measure the immune response through the identification of specific antibodies. Detecting HEV RNA in biological samples is considered the gold standard for confirming acute HEV infection. Nevertheless, it’s essential to take into account the limitations and the timing of these diagnostic approaches [133, 135, 139].

Treatment

Since the HEV infection is may self-limiting, most patients do not require specific treatment. Hospitalization in an intensive care unit is imperative for individuals suffering from acute or acute-on-chronic liver failure. Interventions to address cerebral edema must be implemented, and there may be a need for liver transplantation [5]. At present, there are no approved medications for HEV treatment, but patients receive broad-spectrum antiviral drugs, such as PegIFN2alpha and ribavirin [140].

Ribavirin is given orally twice a day, starting with a daily dose of 600 to 1000 mg, which varies based on the patient’s hemoglobin level and comorbidities. If the hemoglobin level decreases or patients experience symptoms related to anemia, the dosage is decreased. Typically, the intended treatment duration for chronic HEV is 5 months, based on earlier reports suggesting that a shorter treatment period of 3 months could lead to viral relapse [141]. A 3-month treatment regimen of pegylated interferon therapy (weekly dose of 135 µg) was administered to a kidney transplant patient under hemodialysis with chronic HEV infection and successfully attained sustained viral response [142]. In the case of solid organ transplant (SOT) patients with chronic infection, the initial approach to treatment involves reducing immunosuppressive therapy, specifically medications that affect T-cell function. If HEV is not successfully cleared, the next step is administering ribavirin as the sole therapy [143].

Pegylated-interferon-α has proven effective in the treatment of certain liver transplant recipients, and a hemodialysis patient managed to achieve HEV clearance after a three-month treatment regimen. Nevertheless, it is generally not recommended to use interferon for individuals who have undergone kidney, pancreas, heart, or lung transplants. This is because interferon can activate the immune system and enhance the risk of acute rejection [144, 145].

Treatment failure

A systematic review and meta-analysis on chronic HEV cases (395 cases) reported a 78% sustained virological response (SVR) with ribavirin administration. Rapid virological response (RVR) was achieved by 25%, while relapse was observed in 18% of cases. Second ribavirin treatment caused a 76% SVR [146]. Although ribavirin is the key treatment for HEV infection, examination of the evolutionary changes within the HEV population inside a host showed that ribavirin efficacy could be compromised and cause treatment failures [147]. HEV genome alterations were observed, particularly during ribavirin monotherapy in infected patients [148]. In a chronically HEV-infected patient who failed ribavirin treatment due to a fully resistant phenotype, the Y1320H, K1383N, and G1634R mutations in the viral RdRp were linked to ribavirin resistance. In vitro investigation showed that the Y1320H and G1634R mutations and the hypervariable region insertion increased viral replication [149]. In line with previous studies, research confirmed that the Y1320H mutation increases viral replication during acute HEV-3ra infection in rabbits [150]. However, study on solid-organ transplant cases with chronic HEV yielded divergent results, asserting that the presence of the 1634R variant at the onset of ribavirin treatment does not confer complete resistance to ribavirin. Among 63 patients, 42 achieved SVR while 21 did not, with the 1634R variant detected in 36.5% (23/63) of cases. The 1634R variant was found in 31% of baseline plasma samples of SVR cases and in 47.6% of non-SVR cases. This mutation did not affect the initial drop in viral RNA, and a second extended ribavirin treatment resulted in SVR in 70% of the non-SVR patients, despite the mutation [151]. In the context of HEV genetic heterogeneity induced by ribavirin, Meister et al. reported that the single-nucleotide variant (SNV) in ORF2 of HEV caused by ribavirin, generates defective HEV particles that act as immune decoys. The SNV of HEV ORF2 resulted in smaller, noninfectious particles, capable of interfering with antibody neutralization. This variant may act as an immune decoy despite its loss of infectiousness [152].

Vaccines

Given HEV’s global spread and its potential to cause large outbreaks in low-income countries, there is an urgent need for a widely available HEV vaccine [153]. Initial findings from the inaugural human trial carried out at the Walter Reed Army Institute of Research in the US recommended that the recombinant HEV (rHEV) vaccine was both safe and immunogenic. The vaccine consists of polypeptide from insect cells (Sf9) infected with recombinant baculoviruses encompassing a ORF2 of HEV from a 1987 outbreak in Sargodha, Pakistan [154]. The rHEV vaccine was evaluated in 1,794 healthy adults from Nepal who were vulnerable to HEV infection, in 3 doses (at months 0, 1, and 6). The vaccine had an efficacy rate of 95.5% [155].

Several potential HEV vaccines are presently under development. Nevertheless, Hecolin® is the sole licensed vaccine accessible in China since 2012. It consists of a recombinant truncated ORF2 protein HEV239 (aa368-606) that includes 23 nm VLPs which expressed in Escherichia coli [156]. It has undergone multiple clinical trials involving the application of three doses at intervals of 0, 1, and 6 months. In the phase III clinical study that included 48,693 in vaccine group and 48,663 in placebo group ranging from 16 to 65 years of age, it was proven that this vaccine is effective and few and mild side effects related to it were reported [157]. A recent clinical trial showed Hecolin’s safety and immunogenicity, with all participants seroconverting after one month and maintaining IgG responses through six months [158].

In addition to Hecolin, several candidate vaccines for HEV are presently in development, and they primarily focus on the ORF2 structural capsid protein, which envelops the viral particles [156]. Multiple expression systems are utilized during the advancement of these vaccines [159, 160]. A limited number of vaccines are currently in development to offer combined protection against two separate pathogens: hepatitis E and A including HE vaccine HEVp179 and inactivated HA vaccine [161]. Nonetheless, only a single vaccine for HEV has obtained licensing for use in China [162]. Further investigation is needed to establish its effectiveness in populations at high risk, particularly pregnant women, utilizing fast-tracked vaccine schedules that are appropriate for circumstances involving an outbreak [163].

Development of new drug

Ribavirin clears the HEV just in 80% of treated patients and, like pegylated interferon-alpha, is unsuitable for use in pregnancy, underscoring the urgent need for alternative therapies [164]. Sofosbuvir is a prodrug that undergoes triphosphorylation within cells and functions as an analogue of the uridine nucleotide [165]. It is a candidate for HEV treatment that showed inconclusive efficacy [164]. Dao Thi et al. reported that Sofosbuvir could hinder the replication of G3-HEV in subgenomic replicon systems and full-length infectious clones and pairing Sofosbuvir with Ribavirin enhances the antiviral impact [166]. However, a Phase II pilot study on 9 patients indicated that using Sofosbuvir alone doesn’t successfully eliminate HEV RNA in patients suffering from chronic HEV and exhibited just a modest anti-HEV efficacy [167]. Moreover, André et al. found that a single amino acid change (A1343V) in the ORF1 region of HEV may reduce the effectiveness of sofosbuvir treatment in 8 out of 9 patients [168]. In the context of screening leading drug repurposing, Guo et al. identified vidofludimus calcium and pyrazofurin as new HEV treatments. Both drugs effectively suppress HEV replication in human primary liver organoids, reducing the pyrimidine nucleotide pool, enhancing the antiviral effects of IFN-α against HEV, and successfully inhibiting HEV mutants (Y1320H, G1634R) associated with ribavirin treatment failure [169]. The nucleoside analogue 2’-C-methylcytidine effectively blocked HEV replication and maintained its potency over long-term use. Nevertheless, combining it with Ribavirin has counterproductive effects [170]. NITD008 is an adenosine nucleoside analogue that acts as an RdRp inhibitor and could be HEV treatment. It showed less effectiveness in cells derived from neurons compared to those from hepatoma [171]. In another study, favipiravir (polymerase inhibitor), when used together with sofosbuvir, had an additive impact against HEV and inhibited HEV RNA copies by nearly 90% [172]. Efforts to discover alternative treatments for cases where ribavirin is ineffective will persist.

Control measures

The prevention of HEV infections can be accomplished through primary approaches such as access to clean drinking water, managing human waste properly, promoting good personal hygiene practices and generating immunity via vaccination [5]. In developed nations, prevention is a more intricate process due to multiple routes of infection that are not fully understood. However, there are several recommended approaches It is recommended to cook meat products thoroughly, follow proper handling procedures for raw meat. As well, vaccination against HEV has become a realistic possibility [173].

To avoid HEV infection, safeguarding water supplies, and appropriate removal of human feces is of utmost importance. In outbreak settings, it’s essential to adhere to strict sanitation protocols, boiling and chlorination of water. Enhancements in the storage, treatment, and distribution of drinking water, along with improved community sanitation and sewage control, can contribute to a reduction in HEV transmission. In high-risk communities, promoting knowledge about personal and environmental hygiene for better health is equally significant. Surveillance for HEV can aid in early outbreak identification and recommendation of prophylactic measures. Chlorination water supplies and boiling importing drinking water during suspected HEV epidemics are additional preventive measures [5, 174]. However, it is important to note that there have been instances where the introduction of chlorine into the water distribution system during an HEV epidemic, such as the one in Darfur, Sudan in 2004, was found to be insufficient to preventing new infections [175]. Travelers to endemic regions should implement habits like staying away from untreated drinking water, avoiding iced beverages of unknown quality, and refraining from consuming raw shellfish, fruits, or vegetables. Vaccines for HEV are obtainable in China, but they lack FDA endorsement and research on immunoglobulin prophylaxis for HEV prevention is controversial [83, 176].

Future perspectives

Hepatitis E is a public health concern, especially in developing countries with poor sanitation. In the context of HEV diagnosis, HEV RNA is present in the blood and stool for a relatively short period, making timely PCR testing crucial for accurate detection. Additionally, diagnosing HEV in transplant patients using serological methods can be challenging due to the effects of immunosuppressive drugs. Improved diagnostic capabilities and increased awareness about this infection will likely lead to better detection and reporting of HEV cases. The HEV vaccine (Hecolin) is currently available, and ongoing research aims to expand vaccination availability globally. Hecolin is administered in a three-dose schedule, providing longer duration of immunity and higher efficacy. However, in developing countries with poor sanitation where HEV is endemic, adhering to a multi-dose schedule can be challenging. These regions often face limited access to healthcare facilities, logistical difficulties, and increased costs related to vaccine storage, transportation, and administration. Developing a single-dose vaccine with long-term immunity and high efficacy could overcome these obstacles and significantly aid in eradicating the virus in the future. Research into antiviral treatments specifically targeting HEV is ongoing. Future breakthroughs could offer effective treatment options for those infected, particularly immunocompromised individuals or patients who have not responded to ribavirin treatment. Enhanced management protocols for HEV, especially during pregnancy and for patients with chronic infections, could improve outcomes. Improved sanitation and access to clean water in developing countries will be crucial in reducing HEV transmission. Understanding the genotypic variability and pathogenesis of HEV will aid in developing targeted interventions and treatments. Research on zoonotic transmission of HEV from animals to humans can lead to better control measures in both agricultural and food industries. However, despite advancements, complete eradication of HEV faces challenges due to its zoonotic nature and the need for widespread vaccine coverage and improved global sanitation.

Acknowledgements

Not applicable.

Author contributions

A.L: Conceptualization, Supervision. Z.T, B.M, S.S, A.V.F, M.N, S.K, A.Z, M.M, S.F, M.N: writing original draft, tables. O.S.A, T.F, F.K, M.R: Investigation, validation, Review and editing.

Funding

None.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable .

Consent for publication

All authors agree.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Arash Letafati and Zahra Taghiabadi contributed equally to this work.

Change history

9/10/2024

A Correction to this paper has been published: 10.1186/s12985-024-02490-z
==== Refs
References

1. Khuroo MS Discovery of Hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane Virus Res 2011 161 1 3 14 10.1016/j.virusres.2011.02.007 21320558
Khuroo MS. Discovery of Hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Res. 2011;161(1):3–14.21320558 10.1016/j.virusres.2011.02.007
2. von Wulffen M Westhölter D Lütgehetmann M Pischke S Hepatitis E: still waters run deep J Clin Translational Hepatol 2018 6 1 40
von Wulffen M, Westhölter D, Lütgehetmann M, Pischke S. Hepatitis E: still waters run deep. J Clin Translational Hepatol. 2018;6(1):40.
3. Aslan AT Balaban HY Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment World J Gastroenterol 2020 26 37 5543 10.3748/wjg.v26.i37.5543 33071523
Aslan AT, Balaban HY. Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol. 2020;26(37):5543.33071523 10.3748/wjg.v26.i37.5543
4. Zahmanova G Takova K Lukov GL Andonov A Hepatitis E Virus in domestic ruminants and virus excretion in Milk—A potential source of zoonotic HEV infection Viruses 2024 16 5 684 10.3390/v16050684 38793568
Zahmanova G, Takova K, Lukov GL, Andonov A. Hepatitis E Virus in domestic ruminants and virus excretion in Milk—A potential source of zoonotic HEV infection. Viruses. 2024;16(5):684.38793568 10.3390/v16050684
5. Aggarwal R Jameel S Hepatitis E Hepatology 2011 54 6 2218 26 10.1002/hep.24674 21932388
Aggarwal R, Jameel S. Hepatitis E. Hepatology. 2011;54(6):2218–26.21932388 10.1002/hep.24674
6. Payne C Ellis T Plant S Gregory A Wilcox G Sequence data suggests big liver and spleen disease virus (BLSV) is genetically related to hepatitis E virus Vet Microbiol 1999 68 1–2 119 25 10.1016/S0378-1135(99)00067-X 10501168
Payne C, Ellis T, Plant S, Gregory A, Wilcox G. Sequence data suggests big liver and spleen disease virus (BLSV) is genetically related to hepatitis E virus. Vet Microbiol. 1999;68(1–2):119–25.10501168 10.1016/S0378-1135(99)00067-X
7. Dalton HR Kamar N Baylis SA Moradpour D Wedemeyer H Negro F EASL Clinical Practice guidelines on Hepatitis E virus infection J Hepatol 2018 68 6 1256 71 10.1016/j.jhep.2018.03.005 29609832
Dalton HR, Kamar N, Baylis SA, Moradpour D, Wedemeyer H, Negro F. EASL Clinical Practice guidelines on Hepatitis E virus infection. J Hepatol. 2018;68(6):1256–71.29609832 10.1016/j.jhep.2018.03.005
8. Belei O Ancusa O Mara A Olariu L Amaricai E Folescu R Current paradigm of hepatitis E virus among pediatric and adult patients Front Pead 2021 9 721918 10.3389/fped.2021.721918
Belei O, Ancusa O, Mara A, Olariu L, Amaricai E, Folescu R, et al. Current paradigm of hepatitis E virus among pediatric and adult patients. Front Pead. 2021;9:721918.10.3389/fped.2021.721918
9. Fernández Villalobos NV Kessel B Rodiah I Ott JJ Lange B Krause G Seroprevalence of hepatitis E virus infection in the Americas: estimates from a systematic review and meta-analysis PLoS ONE 2022 17 6 e0269253 10.1371/journal.pone.0269253 35648773
Fernández Villalobos NV, Kessel B, Rodiah I, Ott JJ, Lange B, Krause G. Seroprevalence of hepatitis E virus infection in the Americas: estimates from a systematic review and meta-analysis. PLoS ONE. 2022;17(6):e0269253.35648773 10.1371/journal.pone.0269253
10. Li P Liu J Li Y Su J Ma Z Bramer WM The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis Liver Int 2020 40 7 1516 28 10.1111/liv.14468 32281721
Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM, et al. The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis. Liver Int. 2020;40(7):1516–28.32281721 10.1111/liv.14468
11. Zahmanova G Takova K Tonova V Koynarski T Lukov LL Minkov I The re-emergence of Hepatitis E Virus in Europe and Vaccine Development Viruses 2023 15 7 1558 10.3390/v15071558 37515244
Zahmanova G, Takova K, Tonova V, Koynarski T, Lukov LL, Minkov I, et al. The re-emergence of Hepatitis E Virus in Europe and Vaccine Development. Viruses. 2023;15(7):1558.37515244 10.3390/v15071558
12. Kenney SP Meng X-J Therapeutic targets for the treatment of hepatitis E virus infection Expert Opin Ther Targets 2015 19 9 1245 60 10.1517/14728222.2015.1056155 26073772
Kenney SP, Meng X-J. Therapeutic targets for the treatment of hepatitis E virus infection. Expert Opin Ther Targets. 2015;19(9):1245–60.26073772 10.1517/14728222.2015.1056155
13. Buescher G Ozga AK Lorenz E Pischke S May J Addo MM Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis Liver Int 2021 41 3 449 55 10.1111/liv.14695 33034121
Buescher G, Ozga AK, Lorenz E, Pischke S, May J, Addo MM, et al. Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis. Liver Int. 2021;41(3):449–55.33034121 10.1111/liv.14695
14. Carratalà A Joost S Population density and water balance influence the global occurrence of hepatitis E epidemics Sci Rep 2019 9 1 10042 10.1038/s41598-019-46475-3 31296895
Carratalà A, Joost S. Population density and water balance influence the global occurrence of hepatitis E epidemics. Sci Rep. 2019;9(1):10042.31296895 10.1038/s41598-019-46475-3
15. Santos-Silva S López-López P Gonçalves HM Rivero-Juarez A Van der Poel WH Nascimento MSJ A systematic review and Meta-analysis on Hepatitis E Virus Detection in Farmed ruminants Pathogens 2023 12 4 550 10.3390/pathogens12040550 37111437
Santos-Silva S, López-López P, Gonçalves HM, Rivero-Juarez A, Van der Poel WH, Nascimento MSJ, et al. A systematic review and Meta-analysis on Hepatitis E Virus Detection in Farmed ruminants. Pathogens. 2023;12(4):550.37111437 10.3390/pathogens12040550
16. Ali MM Gul M Imran M Ijaz M Azeem S Ullah A Molecular identification and genotyping of hepatitis E virus from Southern Punjab Pakistan Sci Rep 2024 14 1 223 10.1038/s41598-023-50514-5 38167570
Ali MM, Gul M, Imran M, Ijaz M, Azeem S, Ullah A, et al. Molecular identification and genotyping of hepatitis E virus from Southern Punjab. Pakistan Sci Rep. 2024;14(1):223.38167570 10.1038/s41598-023-50514-5
17. Primadharsini PP Nagashima S Okamoto H Genetic variability and evolution of hepatitis E virus Viruses 2019 11 5 456 10.3390/v11050456 31109076
Primadharsini PP, Nagashima S, Okamoto H. Genetic variability and evolution of hepatitis E virus. Viruses. 2019;11(5):456.31109076 10.3390/v11050456
18. Khuroo MS Khuroo MS Khuroo NS Transmission of Hepatitis E Virus in developing countries Viruses 2016 8 9 253 10.3390/v8090253 27657112
Khuroo MS, Khuroo MS, Khuroo NS. Transmission of Hepatitis E Virus in developing countries. Viruses. 2016;8(9):253.27657112 10.3390/v8090253
19. Vitral CL da Silva-Nunes M Pinto MA de Oliveira JM Gaspar AMC Pereira RCC Hepatitis A and E seroprevalence and associated risk factors: a community-based cross-sectional survey in rural Amazonia BMC Infect Dis 2014 14 1 9 10.1186/1471-2334-14-458 24380631
Vitral CL, da Silva-Nunes M, Pinto MA, de Oliveira JM, Gaspar AMC, Pereira RCC, et al. Hepatitis A and E seroprevalence and associated risk factors: a community-based cross-sectional survey in rural Amazonia. BMC Infect Dis. 2014;14:1–9.24380631 10.1186/1471-2334-14-458
20. Berke T Matson D Reclassification of the Caliciviridae into distinct genera and exclusion of hepatitis E virus from the family on the basis of comparative phylogenetic analysis Arch Virol 2000 145 1421 36 10.1007/s007050070099 10963346
Berke T, Matson D. Reclassification of the Caliciviridae into distinct genera and exclusion of hepatitis E virus from the family on the basis of comparative phylogenetic analysis. Arch Virol. 2000;145:1421–36.10963346 10.1007/s007050070099
21. Emerson SU Nguyen H Graff J Stephany DA Brockington A Purcell RH In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein J Virol 2004 78 9 4838 46 10.1128/JVI.78.9.4838-4846.2004 15078965
Emerson SU, Nguyen H, Graff J, Stephany DA, Brockington A, Purcell RH. In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J Virol. 2004;78(9):4838–46.15078965 10.1128/JVI.78.9.4838-4846.2004
22. King AM, Lefkowitz E, Adams MJ, Carstens EB. Virus taxonomy: ninth report of the International Committee on Taxonomy of viruses. Elsevier; 2011.
23. Nerc J, Szeleszczuk P. Classification, structure and molecular diagnostics of avian hepatitis E virus. 2019.
24. Yamashita T, Mori Y, Miyazaki N, Cheng RH, Yoshimura M, Unno H et al. Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proceedings of the National Academy of Sciences. 2009;106(31):12986-91.
25. Kelly AG Netzler NE White PA Ancient recombination events and the origins of hepatitis E virus BMC Evol Biol 2016 16 1 18 10.1186/s12862-016-0785-y 26727998
Kelly AG, Netzler NE, White PA. Ancient recombination events and the origins of hepatitis E virus. BMC Evol Biol. 2016;16:1–18.26727998 10.1186/s12862-016-0785-y
26. Wang B Meng X-J Structural and molecular biology of hepatitis E virus Comput Struct Biotechnol J 2021 19 1907 16 10.1016/j.csbj.2021.03.038 33995894
Wang B, Meng X-J. Structural and molecular biology of hepatitis E virus. Comput Struct Biotechnol J. 2021;19:1907–16.33995894 10.1016/j.csbj.2021.03.038
27. Parvez MK Geometric architecture of viruses World J Virol 2020 9 2 5 10.5501/wjv.v9.i2.5 32923381
Parvez MK. Geometric architecture of viruses. World J Virol. 2020;9(2):5.32923381 10.5501/wjv.v9.i2.5
28. Dong J Dong L Méndez E Tao Y Crystal structure of the human astrovirus capsid spike Proc Natl Acad Sci 2011 108 31 12681 6 10.1073/pnas.1104834108 21768348
Dong J, Dong L, Méndez E, Tao Y. Crystal structure of the human astrovirus capsid spike. Proc Natl Acad Sci. 2011;108(31):12681–6.21768348 10.1073/pnas.1104834108
29. Prpić J, Baymakova M. Hepatitis E virus (HEV) infection among humans and animals: epidemiology, clinical characteristics, treatment, and prevention. MDPI; 2023. p. 931.
30. Purdy MA Drexler JF Meng X-J Norder H Okamoto H Van der Poel WH ICTV virus taxonomy profile: Hepeviridae 2022 J Gen Virol 2022 103 9 001778 10.1099/jgv.0.001778
Purdy MA, Drexler JF, Meng X-J, Norder H, Okamoto H, Van der Poel WH, et al. ICTV virus taxonomy profile: Hepeviridae 2022. J Gen Virol. 2022;103(9):001778.10.1099/jgv.0.001778
31. Di Profio F Sarchese V Palombieri A Fruci P Lanave G Robetto S Current knowledge of hepatitis E virus (HEV) epidemiology in ruminants Pathogens 2022 11 10 1124 10.3390/pathogens11101124 36297181
Di Profio F, Sarchese V, Palombieri A, Fruci P, Lanave G, Robetto S, et al. Current knowledge of hepatitis E virus (HEV) epidemiology in ruminants. Pathogens. 2022;11(10):1124.36297181 10.3390/pathogens11101124
32. Kamani L Padhani ZA Das JK Hepatitis E Genotypes, strategies to prevent and manage, and the existing knowledge gaps JGH Open 2021 5 10 1127 34 10.1002/jgh3.12646 34621997
Kamani L, Padhani ZA, Das JK, Hepatitis E. Genotypes, strategies to prevent and manage, and the existing knowledge gaps. JGH Open. 2021;5(10):1127–34.34621997 10.1002/jgh3.12646
33. Proudfoot A, Hyrina A, Holdorf M, Frank AO, Bussiere D. First crystal structure of a nonstructural hepatitis E viral protein identifies a putative novel zinc-binding protein. J Virol. 2019;93(13). 10.1128/jvi. 00170 – 19.
34. Nair VP Anang S Subramani C Madhvi A Bakshi K Srivastava A Endoplasmic reticulum stress induced synthesis of a novel viral factor mediates efficient replication of genotype-1 hepatitis E virus PLoS Pathog 2016 12 4 e1005521 10.1371/journal.ppat.1005521 27035822
Nair VP, Anang S, Subramani C, Madhvi A, Bakshi K, Srivastava A, et al. Endoplasmic reticulum stress induced synthesis of a novel viral factor mediates efficient replication of genotype-1 hepatitis E virus. PLoS Pathog. 2016;12(4):e1005521.27035822 10.1371/journal.ppat.1005521
35. Graff J Torian U Nguyen H Emerson SU A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus J Virol 2006 80 12 5919 26 10.1128/JVI.00046-06 16731930
Graff J, Torian U, Nguyen H, Emerson SU. A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus. J Virol. 2006;80(12):5919–26.16731930 10.1128/JVI.00046-06
36. Magden J Takeda N Li T Auvinen P Ahola T Miyamura T Virus-specific mRNA capping enzyme encoded by hepatitis E virus J Virol 2001 75 14 6249 55 10.1128/JVI.75.14.6249-6255.2001 11413290
Magden J, Takeda N, Li T, Auvinen P, Ahola T, Miyamura T, et al. Virus-specific mRNA capping enzyme encoded by hepatitis E virus. J Virol. 2001;75(14):6249–55.11413290 10.1128/JVI.75.14.6249-6255.2001
37. Yin X Li X Ambardekar C Hu Z Lhomme S Feng Z Hepatitis E virus persists in the presence of a type III interferon response PLoS Pathog 2017 13 5 e1006417 10.1371/journal.ppat.1006417 28558073
Yin X, Li X, Ambardekar C, Hu Z, Lhomme S, Feng Z. Hepatitis E virus persists in the presence of a type III interferon response. PLoS Pathog. 2017;13(5):e1006417.28558073 10.1371/journal.ppat.1006417
38. Ju X Ding Q Hepatitis E virus assembly and release Viruses 2019 11 6 539 10.3390/v11060539 31181848
Ju X, Ding Q. Hepatitis E virus assembly and release. Viruses. 2019;11(6):539.31181848 10.3390/v11060539
39. Meng X Hepatitis E Virus: animal reservoirs and zoonotic risk Vet Microbiol 2010 140 3–4 256 65 10.1016/j.vetmic.2009.03.017 19361937
Meng X, Hepatitis E. Virus: animal reservoirs and zoonotic risk. Vet Microbiol. 2010;140(3–4):256–65.19361937 10.1016/j.vetmic.2009.03.017
40. Song Y-J Park W-J Park B-J Lee J-B Park S-Y Song C-S Hepatitis E virus infections in humans and animals Clin Experimental Vaccine Res 2014 3 1 29 36 10.7774/cevr.2014.3.1.29
Song Y-J, Park W-J, Park B-J, Lee J-B, Park S-Y, Song C-S, et al. Hepatitis E virus infections in humans and animals. Clin Experimental Vaccine Res. 2014;3(1):29–36.10.7774/cevr.2014.3.1.29
41. Lee G-H Tan B-H Teo EC-Y Lim S-G Dan Y-Y Wee A Chronic infection with camelid hepatitis E virus in a liver transplant recipient who regularly consumes camel meat and milk Gastroenterology 2016 150 2 355 7 10.1053/j.gastro.2015.10.048 26551551
Lee G-H, Tan B-H, Teo EC-Y, Lim S-G, Dan Y-Y, Wee A, et al. Chronic infection with camelid hepatitis E virus in a liver transplant recipient who regularly consumes camel meat and milk. Gastroenterology. 2016;150(2):355–7. e3.26551551 10.1053/j.gastro.2015.10.048
42. Nelson KE Labrique AB Kmush BL Epidemiology of genotype 1 and 2 hepatitis E virus infections Cold Spring Harbor Perspect Med 2019 9 6 a031732 10.1101/cshperspect.a031732
Nelson KE, Labrique AB, Kmush BL. Epidemiology of genotype 1 and 2 hepatitis E virus infections. Cold Spring Harbor Perspect Med. 2019;9(6):a031732.10.1101/cshperspect.a031732
43. Bouamra Y Gérolami R Arzouni J-P Grimaud J-C Lafforgue P Nelli M Emergence of autochthonous infections with hepatitis E virus of genotype 4 in Europe Intervirology 2013 57 1 43 8 10.1159/000354801 24157452
Bouamra Y, Gérolami R, Arzouni J-P, Grimaud J-C, Lafforgue P, Nelli M, et al. Emergence of autochthonous infections with hepatitis E virus of genotype 4 in Europe. Intervirology. 2013;57(1):43–8.24157452 10.1159/000354801
44. Khuroo MS Discovery of Hepatitis E and its impact on global health: a journey of 44 years about an incredible human-interest story Viruses 2023 15 8 1745 10.3390/v15081745 37632090
Khuroo MS. Discovery of Hepatitis E and its impact on global health: a journey of 44 years about an incredible human-interest story. Viruses. 2023;15(8):1745.37632090 10.3390/v15081745
45. Naik S Aggarwal R Salunke P Mehrotra N A large waterborne viral hepatitis E epidemic in Kanpur, India Bull World Health Organ 1992 70 5 597 1464145
Naik S, Aggarwal R, Salunke P, Mehrotra N. A large waterborne viral hepatitis E epidemic in Kanpur, India. Bull World Health Organ. 1992;70(5):597.1464145
46. Hakim MS Wang W Bramer WM Geng J Huang F de Man RA The global burden of hepatitis E outbreaks: a systematic review Liver Int 2017 37 1 19 31 10.1111/liv.13237 27542764
Hakim MS, Wang W, Bramer WM, Geng J, Huang F, de Man RA, et al. The global burden of hepatitis E outbreaks: a systematic review. Liver Int. 2017;37(1):19–31.27542764 10.1111/liv.13237
47. Kuniholm MH Purcell RH McQuillan GM Engle RE Wasley A Nelson KE Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988–1994 J Infect Dis 2009 200 1 48 56 10.1086/599319 19473098
Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988–1994. J Infect Dis. 2009;200(1):48–56.19473098 10.1086/599319
48. Zhang L Yesupriya A Chang MH Teshale E Teo CG Apolipoprotein E and protection against hepatitis E viral infection in American non-hispanic blacks Hepatology 2015 62 5 1346 52 10.1002/hep.27938 26096528
Zhang L, Yesupriya A, Chang MH, Teshale E, Teo CG. Apolipoprotein E and protection against hepatitis E viral infection in American non-hispanic blacks. Hepatology. 2015;62(5):1346–52.26096528 10.1002/hep.27938
49. Lopes T Cable R Pistorius C Maponga T Ijaz S Preiser W Racial differences in seroprevalence of HAV and HEV in blood donors in the Western Cape, South Africa: a clue to the predominant HEV genotype? Epidemiol Infect 2017 145 9 1910 2 10.1017/S0950268817000565 28357965
Lopes T, Cable R, Pistorius C, Maponga T, Ijaz S, Preiser W, et al. Racial differences in seroprevalence of HAV and HEV in blood donors in the Western Cape, South Africa: a clue to the predominant HEV genotype? Epidemiol Infect. 2017;145(9):1910–2.28357965 10.1017/S0950268817000565
50. Khuroo M, Hepatitis E. the enterically transmitted non-A, non-B hepatitis. 1991.
51. Wang B Meng X-J Hepatitis E virus: host tropism and zoonotic infection Curr Opin Microbiol 2021 59 8 15 10.1016/j.mib.2020.07.004 32810801
Wang B, Meng X-J. Hepatitis E virus: host tropism and zoonotic infection. Curr Opin Microbiol. 2021;59:8–15.32810801 10.1016/j.mib.2020.07.004
52. Fenaux H Chassaing M Berger S Gantzer C Bertrand I Schvoerer E Transmission of hepatitis E virus by water: an issue still pending in industrialized countries Water Res 2019 151 144 57 10.1016/j.watres.2018.12.014 30594083
Fenaux H, Chassaing M, Berger S, Gantzer C, Bertrand I, Schvoerer E. Transmission of hepatitis E virus by water: an issue still pending in industrialized countries. Water Res. 2019;151:144–57.30594083 10.1016/j.watres.2018.12.014
53. Yugo DM Meng X-J Hepatitis E virus: foodborne, waterborne and zoonotic transmission Int J Environ Res Public Health 2013 10 10 4507 33 10.3390/ijerph10104507 24071919
Yugo DM, Meng X-J, Hepatitis. E virus: foodborne, waterborne and zoonotic transmission. Int J Environ Res Public Health. 2013;10(10):4507–33.24071919 10.3390/ijerph10104507
54. Miyashita K Kang JH Saga A Takahashi K Shimamura T Yasumoto A Three cases of acute or fulminant hepatitis E caused by ingestion of pork meat and entrails in Hokkaido, Japan: zoonotic food-borne transmission of hepatitis E virus and public health concerns Hepatol Res 2012 42 9 870 8 10.1111/j.1872-034X.2012.01006.x 22568494
Miyashita K, Kang JH, Saga A, Takahashi K, Shimamura T, Yasumoto A, et al. Three cases of acute or fulminant hepatitis E caused by ingestion of pork meat and entrails in Hokkaido, Japan: zoonotic food-borne transmission of hepatitis E virus and public health concerns. Hepatol Res. 2012;42(9):870–8.22568494 10.1111/j.1872-034X.2012.01006.x
55. Colson P Borentain P Queyriaux B Kaba M Moal V Gallian P Pig liver sausage as a source of hepatitis E virus transmission to humans J Infect Dis 2010 202 6 825 34 10.1086/655898 20695796
Colson P, Borentain P, Queyriaux B, Kaba M, Moal V, Gallian P, et al. Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis. 2010;202(6):825–34.20695796 10.1086/655898
56. Bouwknegt M Engel B Herremans M Widdowson M Worm H Koopmans M Bayesian estimation of hepatitis E virus seroprevalence for populations with different exposure levels to swine in the Netherlands Epidemiol Infect 2008 136 4 567 76 10.1017/S0950268807008941 17578603
Bouwknegt M, Engel B, Herremans M, Widdowson M, Worm H, Koopmans M, et al. Bayesian estimation of hepatitis E virus seroprevalence for populations with different exposure levels to swine in the Netherlands. Epidemiol Infect. 2008;136(4):567–76.17578603 10.1017/S0950268807008941
57. Rutjes SA Lodder WJ Lodder-Verschoor F Van den Berg HH Vennema H Duizer E Sources of hepatitis E virus genotype 3 in the Netherlands Emerg Infect Dis 2009 15 3 381 10.3201/eid1503.071472 19239749
Rutjes SA, Lodder WJ, Lodder-Verschoor F, Van den Berg HH, Vennema H, Duizer E, et al. Sources of hepatitis E virus genotype 3 in the Netherlands. Emerg Infect Dis. 2009;15(3):381.19239749 10.3201/eid1503.071472
58. Sarno E Martin A McFarland S Johne R Stephan R Greiner M Estimated exposure to hepatitis E virus through consumption of swine liver and liver sausages Food Control 2017 73 821 8 10.1016/j.foodcont.2016.09.030
Sarno E, Martin A, McFarland S, Johne R, Stephan R, Greiner M. Estimated exposure to hepatitis E virus through consumption of swine liver and liver sausages. Food Control. 2017;73:821–8.10.1016/j.foodcont.2016.09.030
59. Walachowski S Dorenlor V Lefevre J Lunazzi A Eono F Merbah T Risk factors associated with the presence of hepatitis E virus in livers and seroprevalence in slaughter-age pigs: a retrospective study of 90 swine farms in France Epidemiol Infect 2014 142 9 1934 44 10.1017/S0950268813003063 24284046
Walachowski S, Dorenlor V, Lefevre J, Lunazzi A, Eono F, Merbah T, et al. Risk factors associated with the presence of hepatitis E virus in livers and seroprevalence in slaughter-age pigs: a retrospective study of 90 swine farms in France. Epidemiol Infect. 2014;142(9):1934–44.24284046 10.1017/S0950268813003063
60. Taus K Schmoll F El-Khatib Z Auer H Holzmann H Aberle S Occupational swine exposure and Hepatitis E virus, Leptospira, Ascaris suum seropositivity and MRSA colonization in Austrian veterinarians, 2017–2018—A cross‐sectional study Zoonoses Public Health 2019 66 7 842 51 10.1111/zph.12633 31419070
Taus K, Schmoll F, El-Khatib Z, Auer H, Holzmann H, Aberle S, et al. Occupational swine exposure and Hepatitis E virus, Leptospira, Ascaris suum seropositivity and MRSA colonization in Austrian veterinarians, 2017–2018—A cross‐sectional study. Zoonoses Public Health. 2019;66(7):842–51.31419070 10.1111/zph.12633
61. Ward P Müller P Letellier A Quessy S Simard C Trottier Y-L Molecular characterization of hepatitis E virus detected in swine farms in the province of Quebec Can J Vet Res 2008 72 1 27 18214158
Ward P, Müller P, Letellier A, Quessy S, Simard C, Trottier Y-L, et al. Molecular characterization of hepatitis E virus detected in swine farms in the province of Quebec. Can J Vet Res. 2008;72(1):27.18214158
62. Brassard J Gagné M-J Généreux M Côté C Detection of human food-borne and zoonotic viruses on irrigated, field-grown strawberries Appl Environ Microbiol 2012 78 10 3763 6 10.1128/AEM.00251-12 22427499
Brassard J, Gagné M-J, Généreux M, Côté C. Detection of human food-borne and zoonotic viruses on irrigated, field-grown strawberries. Appl Environ Microbiol. 2012;78(10):3763–6.22427499 10.1128/AEM.00251-12
63. Steyer A Naglič T Močilnik T Poljšak-Prijatelj M Poljak M Hepatitis E virus in domestic pigs and surface waters in Slovenia: prevalence and molecular characterization of a novel genotype 3 lineage Infect Genet Evol 2011 11 7 1732 7 10.1016/j.meegid.2011.07.007 21802527
Steyer A, Naglič T, Močilnik T, Poljšak-Prijatelj M, Poljak M. Hepatitis E virus in domestic pigs and surface waters in Slovenia: prevalence and molecular characterization of a novel genotype 3 lineage. Infect Genet Evol. 2011;11(7):1732–7.21802527 10.1016/j.meegid.2011.07.007
64. Tyrrel S Quinton J Overland flow transport of pathogens from agricultural land receiving faecal wastes J Appl Microbiol 2003 94 s1 87 93 10.1046/j.1365-2672.94.s1.10.x
Tyrrel S, Quinton J. Overland flow transport of pathogens from agricultural land receiving faecal wastes. J Appl Microbiol. 2003;94(s1):87–93.10.1046/j.1365-2672.94.s1.10.x
65. Namsai A Louisirirotchanakul S Wongchinda N Siripanyaphinyo U Virulhakul P Puthavathana P Surveillance of hepatitis A and E viruses contamination in shellfish in Thailand Lett Appl Microbiol 2011 53 6 608 13 10.1111/j.1472-765X.2011.03152.x 21929540
Namsai A, Louisirirotchanakul S, Wongchinda N, Siripanyaphinyo U, Virulhakul P, Puthavathana P, et al. Surveillance of hepatitis A and E viruses contamination in shellfish in Thailand. Lett Appl Microbiol. 2011;53(6):608–13.21929540 10.1111/j.1472-765X.2011.03152.x
66. Rivero-Juarez A Lopez-Lopez P Hepatitis E infection in HIV-infected patients Front Microbiol 2019 10 470960 10.3389/fmicb.2019.01425
Rivero-Juarez A, Lopez-Lopez P. Hepatitis E infection in HIV-infected patients. Front Microbiol. 2019;10:470960.10.3389/fmicb.2019.01425
67. Dalton HR Kamar N Van Eijk JJ Mclean BN Cintas P Bendall RP Hepatitis E virus and neurological injury Nat Reviews Neurol 2016 12 2 77 10.1038/nrneurol.2015.234
Dalton HR, Kamar N, Van Eijk JJ, Mclean BN, Cintas P, Bendall RP, et al. Hepatitis E virus and neurological injury. Nat Reviews Neurol. 2016;12(2):77.10.1038/nrneurol.2015.234
68. Williams TPE Kasorndorkbua C Halbur P Haqshenas G Guenette D Toth T Evidence of extrahepatic sites of replication of the hepatitis E virus in a swine model J Clin Microbiol 2001 39 9 3040 6 10.1128/JCM.39.9.3040-3046.2001 11526125
Williams TPE, Kasorndorkbua C, Halbur P, Haqshenas G, Guenette D, Toth T, et al. Evidence of extrahepatic sites of replication of the hepatitis E virus in a swine model. J Clin Microbiol. 2001;39(9):3040–6.11526125 10.1128/JCM.39.9.3040-3046.2001
69. Liu P Bu Q-N Wang L Han J Du R-J Lei Y-X Transmission of hepatitis E virus from rabbits to cynomolgus macaques Emerg Infect Dis 2013 19 4 559 10.3201/eid1904.120827 23628346
Liu P, Bu Q-N, Wang L, Han J, Du R-J, Lei Y-X, et al. Transmission of hepatitis E virus from rabbits to cynomolgus macaques. Emerg Infect Dis. 2013;19(4):559.23628346 10.3201/eid1904.120827
70. Debing Y Moradpour D Neyts J Gouttenoire J Update on hepatitis E virology: implications for clinical practice J Hepatol 2016 65 1 200 12 10.1016/j.jhep.2016.02.045 26966047
Debing Y, Moradpour D, Neyts J, Gouttenoire J. Update on hepatitis E virology: implications for clinical practice. J Hepatol. 2016;65(1):200–12.26966047 10.1016/j.jhep.2016.02.045
71. Shahini E Argentiero A Andriano A Losito F Maida M Facciorusso A Hepatitis E Virus: what more do we need to know? Medicina 2024 60 6 998 10.3390/medicina60060998 38929615
Shahini E, Argentiero A, Andriano A, Losito F, Maida M, Facciorusso A, et al. Hepatitis E Virus: what more do we need to know? Medicina. 2024;60(6):998.38929615 10.3390/medicina60060998
72. Kamar N Mansuy JM Esposito L Legrand-Abravanel F Peron JM Durand D Acute hepatitis and renal function impairment related to infection by Hepatitis E virus in a renal allograft recipient Am J Kidney Dis 2005 45 1 193 6 10.1053/j.ajkd.2004.09.006 15696460
Kamar N, Mansuy JM, Esposito L, Legrand-Abravanel F, Peron JM, Durand D, et al. Acute hepatitis and renal function impairment related to infection by Hepatitis E virus in a renal allograft recipient. Am J Kidney Dis. 2005;45(1):193–6.15696460 10.1053/j.ajkd.2004.09.006
73. Kamar N Bendall R Legrand-Abravanel F Xia N-S Ijaz S Izopet J Hepatitis E Lancet 2012 379 9835 2477 88 10.1016/S0140-6736(11)61849-7 22549046
Kamar N, Bendall R, Legrand-Abravanel F, Xia N-S, Ijaz S, Izopet J, et al. Hepatitis E. Lancet. 2012;379(9835):2477–88.22549046 10.1016/S0140-6736(11)61849-7
74. Geng Y Zhao C Huang W Harrison TJ Zhang H Geng K Detection and assessment of infectivity of hepatitis E virus in urine J Hepatol 2016 64 1 37 43 10.1016/j.jhep.2015.08.034 26362822
Geng Y, Zhao C, Huang W, Harrison TJ, Zhang H, Geng K, et al. Detection and assessment of infectivity of hepatitis E virus in urine. J Hepatol. 2016;64(1):37–43.26362822 10.1016/j.jhep.2015.08.034
75. Aggarwal R Krawczynski K Hepatitis E An overview and recent advances in clinical and laboratory research J Gastroenterol Hepatol 2000 15 1 9 20 10.1046/j.1440-1746.2000.02006.x 10719741
Aggarwal R, Krawczynski K, Hepatitis E. An overview and recent advances in clinical and laboratory research. J Gastroenterol Hepatol. 2000;15(1):9–20.10719741 10.1046/j.1440-1746.2000.02006.x
76. Izopet J Lhomme S Chapuy-Regaud S Mansuy JM Kamar N Abravanel F HEV and transfusion-recipient risk Transfus Clin Biol 2017 24 3 176 81 10.1016/j.tracli.2017.06.012 28690036
Izopet J, Lhomme S, Chapuy-Regaud S, Mansuy JM, Kamar N, Abravanel F. HEV and transfusion-recipient risk. Transfus Clin Biol. 2017;24(3):176–81.28690036 10.1016/j.tracli.2017.06.012
77. Aggarwal R Clinical presentation of hepatitis E Virus Res 2011 161 1 15 22 10.1016/j.virusres.2011.03.017 21458513
Aggarwal R. Clinical presentation of hepatitis E. Virus Res. 2011;161(1):15–22.21458513 10.1016/j.virusres.2011.03.017
78. Teshale EH Hu DJ Hepatitis E Epidemiology and prevention World J Hepatol 2011 3 12 285 91 10.4254/wjh.v3.i12.285 22216368
Teshale EH, Hu DJ, Hepatitis E. Epidemiology and prevention. World J Hepatol. 2011;3(12):285–91.22216368 10.4254/wjh.v3.i12.285
79. Pischke S Hartl J Pas SD Lohse AW Jacobs BC Van der Eijk AA Hepatitis E virus: infection beyond the liver? J Hepatol 2017 66 5 1082 95 10.1016/j.jhep.2016.11.016 27913223
Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis E virus: infection beyond the liver? J Hepatol. 2017;66(5):1082–95.27913223 10.1016/j.jhep.2016.11.016
80. Nasir M Wu GY HEV and HBV Dual Infection: a review J Clin Transl Hepatol 2020 8 3 313 21 10.14218/JCTH.2020.00030 33083255
Nasir M, Wu GY. HEV and HBV Dual Infection: a review. J Clin Transl Hepatol. 2020;8(3):313–21.33083255 10.14218/JCTH.2020.00030
81. Lhomme S, Marion O, Abravanel F, Chapuy-Regaud S, Kamar N, Izopet J, Hepatitis. E Pathogenesis Viruses. 2016;8(8).
82. Urooj S Anjum S Iqbal F Abduh MS Akhtar H Javed S Hepatitis E Virus: Epidemiology, clinical aspects, and its significance as a major pregnancy risk Livers 2023 3 3 507 28 10.3390/livers3030035
Urooj S, Anjum S, Iqbal F, Abduh MS, Akhtar H, Javed S, et al. Hepatitis E Virus: Epidemiology, clinical aspects, and its significance as a major pregnancy risk. Livers. 2023;3(3):507–28.10.3390/livers3030035
83. Wu C Wu X Xia J Hepatitis E virus infection during pregnancy Virol J 2020 17 1 11 10.1186/s12985-020-01343-9 31906972
Wu C, Wu X, Xia J. Hepatitis E virus infection during pregnancy. Virol J. 2020;17:1–11.31906972 10.1186/s12985-020-01343-9
84. Peron J Bureau C Poirson H Mansuy J Alric L Selves J Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy J Viral Hepatitis 2007 14 5 298 303 10.1111/j.1365-2893.2007.00858.x
Peron J, Bureau C, Poirson H, Mansuy J, Alric L, Selves J, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepatitis. 2007;14(5):298–303.10.1111/j.1365-2893.2007.00858.x
85. Butler DC Lewin DN Batalis NI Differential diagnosis of hepatic necrosis encountered at autopsy Acad Forensic Pathol 2018 8 2 256 95 10.1177/1925362118782056 31240042
Butler DC, Lewin DN, Batalis NI. Differential diagnosis of hepatic necrosis encountered at autopsy. Acad Forensic Pathol. 2018;8(2):256–95.31240042 10.1177/1925362118782056
86. Fousekis FS Mitselos IV Christodoulou DK Extrahepatic manifestations of hepatitis E virus: an overview Clin Mol Hepatol 2020 26 1 16 10.3350/cmh.2019.0082 31601068
Fousekis FS, Mitselos IV, Christodoulou DK. Extrahepatic manifestations of hepatitis E virus: an overview. Clin Mol Hepatol. 2020;26(1):16.31601068 10.3350/cmh.2019.0082
87. Jha AK Kumar G Dayal VM Ranjan A Suchismita A Neurological manifestations of hepatitis E virus infection: an overview World J Gastroenterol 2021 27 18 2090 10.3748/wjg.v27.i18.2090 34025066
Jha AK, Kumar G, Dayal VM, Ranjan A, Suchismita A. Neurological manifestations of hepatitis E virus infection: an overview. World J Gastroenterol. 2021;27(18):2090.34025066 10.3748/wjg.v27.i18.2090
88. Rawla P Raj JP Kannemkuzhiyil AJ Aluru JS Thandra KC Gajendran M A systematic review of the extra-hepatic manifestations of hepatitis E virus infection Med Sci 2020 8 1 9
Rawla P, Raj JP, Kannemkuzhiyil AJ, Aluru JS, Thandra KC, Gajendran M. A systematic review of the extra-hepatic manifestations of hepatitis E virus infection. Med Sci. 2020;8(1):9.
89. de Vries MA Samijn JP de Man R Boots JM Hepatitis E-associated encephalopathy in a renal transplant recipient Case Rep 2014 2014 bcr2014204244
de Vries MA, Samijn JP, de Man R, Boots JM. Hepatitis E-associated encephalopathy in a renal transplant recipient. Case Rep. 2014;2014:bcr2014204244.
90. Woolson K Forbes A Vine L Beynon L McElhinney L Panayi V Extra-hepatic manifestations of autochthonous hepatitis E infection Aliment Pharmacol Ther 2014 40 11–12 1282 91 10.1111/apt.12986 25303615
Woolson K, Forbes A, Vine L, Beynon L, McElhinney L, Panayi V, et al. Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther. 2014;40(11–12):1282–91.25303615 10.1111/apt.12986
91. Vallabhajosyula S Prabhu M Stanley W Vallabhajosyula S 510: Multiorgan Dysfunction from Hepatitis E infection Crit Care Med 2018 46 1 240 10.1097/01.ccm.0000528528.42797.26
Vallabhajosyula S, Prabhu M, Stanley W, Vallabhajosyula S. 510: Multiorgan Dysfunction from Hepatitis E infection. Crit Care Med. 2018;46(1):240.10.1097/01.ccm.0000528528.42797.26
92. Karki P Malik S Mallick B Sharma V Rana SS Massive hemolysis causing renal failure in acute hepatitis E infection J Clin Translational Hepatol 2016 4 4 345
Karki P, Malik S, Mallick B, Sharma V, Rana SS. Massive hemolysis causing renal failure in acute hepatitis E infection. J Clin Translational Hepatol. 2016;4(4):345.
93. Aiqin Z Dongming X Kejun T Yun Z Long qt syndrome and Torsades De Points in a patient with acute hepatitis E virus infection: an unusual case Heart 2012 98 Suppl 2 E222 3 10.1136/heartjnl-2012-302920n.6
Aiqin Z, Dongming X, Kejun T, Yun Z. Long qt syndrome and Torsades De Points in a patient with acute hepatitis E virus infection: an unusual case. Heart. 2012;98(Suppl 2):E222–3.10.1136/heartjnl-2012-302920n.6
94. Somani SK Ghosh A Awasthi G Severe acute pancreatitis with pseudocyst bleeding due to hepatitis E virus infection Clin J Gastroenterol 2009 2 1 39 42 10.1007/s12328-008-0035-y 26191807
Somani SK, Ghosh A, Awasthi G. Severe acute pancreatitis with pseudocyst bleeding due to hepatitis E virus infection. Clin J Gastroenterol. 2009;2(1):39–42.26191807 10.1007/s12328-008-0035-y
95. Petrik J Lozano M Seed CR Faddy HM Keller AJ Prado Scuracchio PS Hepat E Vox Sang 2016 110 1 93 130 10.1111/vox.12285
Petrik J, Lozano M, Seed CR, Faddy HM, Keller AJ, Prado Scuracchio PS, et al. Hepat E Vox Sang. 2016;110(1):93–130.10.1111/vox.12285
96. Smith JL A review of hepatitis E virus J Food Prot 2001 64 4 572 86 10.4315/0362-028X-64.4.572 11307901
Smith JL. A review of hepatitis E virus. J Food Prot. 2001;64(4):572–86.11307901 10.4315/0362-028X-64.4.572
97. Evans AS. Viral infections of humans: epidemiology and control. Springer Science & Business Media; 2013.
98. Aggarwal R, Naik S. Epidemiology of hepatitis E: past, present and future. 1997.
99. Balayan M Epidemiology of hepatitis E virus infection J Viral Hepatitis 1997 4 3 155 66 10.1046/j.1365-2893.1997.00145.x
Balayan M. Epidemiology of hepatitis E virus infection. J Viral Hepatitis. 1997;4(3):155–66.10.1046/j.1365-2893.1997.00145.x
100. Bradley DW Hepatitis E: epidemiology, aetiology and molecular biology Rev Med Virol 1992 2 1 19 28 10.1002/rmv.1980020104
Bradley DW. Hepatitis E: epidemiology, aetiology and molecular biology. Rev Med Virol. 1992;2(1):19–28.10.1002/rmv.1980020104
101. Langer B, Frösner G. Relative importance of the enterically transmitted human hepatitis viruses type A and E as a cause of foreign travel associated hepatitis. Import Virus Infections. 1996:171–9.
102. Ahmad T Nasir S Musa TH AlRyalat SAS Khan M Hui J Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus Hum Vaccines Immunotherapeutics 2021 17 3 857 71 10.1080/21645515.2020.1795458
Ahmad T, Nasir S, Musa TH, AlRyalat SAS, Khan M, Hui J. Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus. Hum Vaccines Immunotherapeutics. 2021;17(3):857–71.10.1080/21645515.2020.1795458
103. Maral I Budakoglu I Ceyhan M Atak A Bumin M Hepatitis E virus seroepidemiology and its change during 1 year in primary school students in Ankara, Turkey Clin Microbiol Infect 2010 16 7 831 5 10.1111/j.1469-0691.2009.02963.x 19778297
Maral I, Budakoglu I, Ceyhan M, Atak A, Bumin M. Hepatitis E virus seroepidemiology and its change during 1 year in primary school students in Ankara, Turkey. Clin Microbiol Infect. 2010;16(7):831–5.19778297 10.1111/j.1469-0691.2009.02963.x
104. Jin H Zhao Y Zhang X Wang B Liu P Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis Epidemiol Infect 2016 144 10 2098 106 10.1017/S0950268816000418 26939626
Jin H, Zhao Y, Zhang X, Wang B, Liu P. Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis. Epidemiol Infect. 2016;144(10):2098–106.26939626 10.1017/S0950268816000418
105. Taherkhani R Farshadpour F Epidemiology of hepatitis E in pregnant women and children in Iran: a general overview J Clin Translational Hepatol 2016 4 3 269
Taherkhani R, Farshadpour F. Epidemiology of hepatitis E in pregnant women and children in Iran: a general overview. J Clin Translational Hepatol. 2016;4(3):269.
106. JOSEPH G PASTOREK I The ABCs of hepatitis in pregnancy Clin Obstet Gynecol 1993 36 4 843 54 10.1097/00003081-199312000-00008 8293586
JOSEPH G PASTOREK I. The ABCs of hepatitis in pregnancy. Clin Obstet Gynecol. 1993;36(4):843–54.8293586 10.1097/00003081-199312000-00008
107. Kamar N Selves J Mansuy J-M Ouezzani L Péron J-M Guitard J Hepatitis E virus and chronic hepatitis in organ-transplant recipients N Engl J Med 2008 358 8 811 7 10.1056/NEJMoa0706992 18287603
Kamar N, Selves J, Mansuy J-M, Ouezzani L, Péron J-M, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811–7.18287603 10.1056/NEJMoa0706992
108. Dalton HR Bendall RP Keane FE Tedder RS Ijaz S Persistent carriage of hepatitis E virus in patients with HIV infection N Engl J Med 2009 361 10 1025 7 10.1056/NEJMc0903778 19726781
Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361(10):1025–7.19726781 10.1056/NEJMc0903778
109. Songtanin B Molehin AJ Brittan K Manatsathit W Nugent K Hepatitis E virus infections: Epidemiology, genetic diversity, and clinical considerations Viruses 2023 15 6 1389 10.3390/v15061389 37376687
Songtanin B, Molehin AJ, Brittan K, Manatsathit W, Nugent K. Hepatitis E virus infections: Epidemiology, genetic diversity, and clinical considerations. Viruses. 2023;15(6):1389.37376687 10.3390/v15061389
110. Kemming J Gundlach S Panning M Huzly D Huang J Lütgehetmann M Mechanisms of CD8 + T-cell failure in chronic hepatitis E virus infection J Hepatol 2022 77 4 978 90 10.1016/j.jhep.2022.05.019 35636577
Kemming J, Gundlach S, Panning M, Huzly D, Huang J, Lütgehetmann M, et al. Mechanisms of CD8 + T-cell failure in chronic hepatitis E virus infection. J Hepatol. 2022;77(4):978–90.35636577 10.1016/j.jhep.2022.05.019
111. Krain LJ Nelson KE Labrique AB Host immune status and response to hepatitis E virus infection Clin Microbiol Rev 2014 27 1 139 65 10.1128/CMR.00062-13 24396140
Krain LJ, Nelson KE, Labrique AB. Host immune status and response to hepatitis E virus infection. Clin Microbiol Rev. 2014;27(1):139–65.24396140 10.1128/CMR.00062-13
112. Zhang JZ Im SW Lau SH Chau TN Lai ST Ng SP Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis J Med Virol 2002 66 1 40 8 10.1002/jmv.2109 11748657
Zhang JZ, Im SW, Lau SH, Chau TN, Lai ST, Ng SP, et al. Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis. J Med Virol. 2002;66(1):40–8.11748657 10.1002/jmv.2109
113. Saravanabalaji S Tripathy AS Dhoot RR Chadha MS Kakrani AL Arankalle VA Viral load, antibody titers and recombinant Open Reading Frame 2 Protein-Induced Th1/Th2 cytokines and Cellular Immune responses in self-limiting and Fulminant Hepatitis E Intervirology 2009 52 2 78 85 10.1159/000214862 19401616
Saravanabalaji S, Tripathy AS, Dhoot RR, Chadha MS, Kakrani AL, Arankalle VA. Viral load, antibody titers and recombinant Open Reading Frame 2 Protein-Induced Th1/Th2 cytokines and Cellular Immune responses in self-limiting and Fulminant Hepatitis E. Intervirology. 2009;52(2):78–85.19401616 10.1159/000214862
114. Srivastava R Aggarwal R Jameel S Puri P Gupta VK Ramesh VS Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein Viral Immunol 2007 20 1 56 65 10.1089/vim.2006.0053 17425421
Srivastava R, Aggarwal R, Jameel S, Puri P, Gupta VK, Ramesh VS, et al. Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol. 2007;20(1):56–65.17425421 10.1089/vim.2006.0053
115. Srivastava R Aggarwal R Bhagat MR Chowdhury A Naik S Alterations in natural killer cells and natural killer T cells during acute viral hepatitis E J Viral Hepat 2008 15 12 910 6 10.1111/j.1365-2893.2008.01036.x 18673427
Srivastava R, Aggarwal R, Bhagat MR, Chowdhury A, Naik S. Alterations in natural killer cells and natural killer T cells during acute viral hepatitis E. J Viral Hepat. 2008;15(12):910–6.18673427 10.1111/j.1365-2893.2008.01036.x
116. Wu J Ling B Guo N Zhai G Li M Guo Y Immunological manifestations of hepatitis e-associated acute and chronic liver failure and its regulatory mechanisms Front Med 2021 8 725993 10.3389/fmed.2021.725993
Wu J, Ling B, Guo N, Zhai G, Li M, Guo Y. Immunological manifestations of hepatitis e-associated acute and chronic liver failure and its regulatory mechanisms. Front Med. 2021;8:725993.10.3389/fmed.2021.725993
117. Bruccoleri A Gallucci R Germolec DR Blackshear P Simeonova P Thurman RG Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity Hepatology 1997 25 1 133 41 10.1002/hep.510250125 8985279
Bruccoleri A, Gallucci R, Germolec DR, Blackshear P, Simeonova P, Thurman RG, et al. Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity. Hepatology. 1997;25(1):133–41.8985279 10.1002/hep.510250125
118. Yamada Y Kirillova I Peschon JJ Fausto N Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor Proc Natl Acad Sci U S A 1997 94 4 1441 6 10.1073/pnas.94.4.1441 9037072
Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A. 1997;94(4):1441–6.9037072 10.1073/pnas.94.4.1441
119. Srivastava R Aggarwal R Sachdeva S Alam MI Jameel S Naik S Adaptive immune responses during acute uncomplicated and fulminant hepatitis E J Gastroenterol Hepatol 2011 26 2 306 11 10.1111/j.1440-1746.2010.06356.x 21143520
Srivastava R, Aggarwal R, Sachdeva S, Alam MI, Jameel S, Naik S. Adaptive immune responses during acute uncomplicated and fulminant hepatitis E. J Gastroenterol Hepatol. 2011;26(2):306–11.21143520 10.1111/j.1440-1746.2010.06356.x
120. Khuroo MS Kamili S Dar MY Moecklii R Jameel S Hepatitis E and long-term antibody status Lancet 1993 341 8856 1355 10.1016/0140-6736(93)90873-F 8098491
Khuroo MS, Kamili S, Dar MY, Moecklii R, Jameel S. Hepatitis E and long-term antibody status. Lancet. 1993;341(8856):1355.8098491 10.1016/0140-6736(93)90873-F
121. Shrivastava S Steele R Ray R Ray RB MicroRNAs: role in hepatitis C virus pathogenesis Genes Dis 2015 2 1 35 45 10.1016/j.gendis.2015.01.001 25984557
Shrivastava S, Steele R, Ray R, Ray RB. MicroRNAs: role in hepatitis C virus pathogenesis. Genes Dis. 2015;2(1):35–45.25984557 10.1016/j.gendis.2015.01.001
122. Xu L-D Zhang F Peng L Luo W-T Chen C Xu P Stable expression of a hepatitis E virus (HEV) RNA replicon in two mammalian cell lines to assess mechanism of innate immunity and antiviral response Front Microbiol 2020 11 603699 10.3389/fmicb.2020.603699 33424806
Xu L-D, Zhang F, Peng L, Luo W-T, Chen C, Xu P, et al. Stable expression of a hepatitis E virus (HEV) RNA replicon in two mammalian cell lines to assess mechanism of innate immunity and antiviral response. Front Microbiol. 2020;11:603699.33424806 10.3389/fmicb.2020.603699
123. Baruah V Bose S Computational identification of hepatitis E virus-encoded microRNAs and their targets in human J Med Virol 2019 91 8 1545 52 10.1002/jmv.25471 30919453
Baruah V, Bose S. Computational identification of hepatitis E virus-encoded microRNAs and their targets in human. J Med Virol. 2019;91(8):1545–52.30919453 10.1002/jmv.25471
124. Chaikuad A Keates T Vincke C Kaufholz M Zenn M Zimmermann B Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies Biochem J 2014 459 1 59 69 10.1042/BJ20131399 24438162
Chaikuad A, Keates T, Vincke C, Kaufholz M, Zenn M, Zimmermann B, et al. Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. Biochem J. 2014;459(1):59–69.24438162 10.1042/BJ20131399
125. Patil RN Karpe YA Uncovering the roles of miR-214 in hepatitis E virus replication J Mol Biol 2020 432 19 5322 42 10.1016/j.jmb.2020.07.015 32735806
Patil RN, Karpe YA. Uncovering the roles of miR-214 in hepatitis E virus replication. J Mol Biol. 2020;432(19):5322–42.32735806 10.1016/j.jmb.2020.07.015
126. Haldipur B Bhukya PL Arankalle V Lole K Positive regulation of hepatitis E virus replication by microRNA-122 J Virol 2018 92 11 01999 17 10.1128/jvi
Haldipur B, Bhukya PL, Arankalle V, Lole K. Positive regulation of hepatitis E virus replication by microRNA-122. J Virol. 2018;92(11):01999–17. 10.1128/jvi.10.1128/jvi
127. Jopling C Liver-specific microRNA-122: Biogenesis and function RNA Biol 2012 9 2 137 42 10.4161/rna.18827 22258222
Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012;9(2):137–42.22258222 10.4161/rna.18827
128. Hu J Xu Y Hao J Wang S Li C Meng S MiR-122 in hepatic function and liver diseases Protein Cell 2012 3 5 364 71 10.1007/s13238-012-2036-3 22610888
Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell. 2012;3(5):364–71.22610888 10.1007/s13238-012-2036-3
129. Spaniel C Honda M Selitsky SR Yamane D Shimakami T Kaneko S microRNA-122 abundance in Hepatocellular Carcinoma and Non-tumor Liver tissue from Japanese patients with persistent HCV versus HBV infection PLoS ONE 2013 8 10 e76867 10.1371/journal.pone.0076867 24130799
Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, et al. microRNA-122 abundance in Hepatocellular Carcinoma and Non-tumor Liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS ONE. 2013;8(10):e76867.24130799 10.1371/journal.pone.0076867
130. McGowan K Simpson KJ Petrik J Expression profiles of exosomal MicroRNAs from HEV-and HCV-infected blood donors and patients: a pilot study Viruses 2020 12 8 833 10.3390/v12080833 32751663
McGowan K, Simpson KJ, Petrik J. Expression profiles of exosomal MicroRNAs from HEV-and HCV-infected blood donors and patients: a pilot study. Viruses. 2020;12(8):833.32751663 10.3390/v12080833
131. Trehanpati N, Sehgal R, Patra S, Vyas A, Vasudevan M, Khosla R et al. miRNA signatures can predict acute liver failure in hepatitis E infected pregnant females. Heliyon. 2017;3(4).
132. Golkocheva-Markova E. Micro RNAs—The Small Big Players in Hepatitis E Virus Infection: A Comprehensive Review. Biomolecules. 2022;12(11):1543.
133. Mirazo S, Ramos N, Mainardi V, Gerona S, Arbiza J. Transmission, diagnosis, and management of hepatitis E: an update. Hepatic Medicine: Evid Res. 2014:45–59.
134. Ahmed A, Ali IA, Ghazal H, Fazili J, Nusrat S. Mystery of hepatitis e virus: recent advances in its diagnosis and management. Int J Hepatol. 2015;2015.
135. Huang S Zhang X Jiang H Yan Q Ai X Wang Y Profile of acute infectious markers in sporadic hepatitis E PLoS ONE 2010 5 10 e13560 10.1371/journal.pone.0013560 21042408
Huang S, Zhang X, Jiang H, Yan Q, Ai X, Wang Y, et al. Profile of acute infectious markers in sporadic hepatitis E. PLoS ONE. 2010;5(10):e13560.21042408 10.1371/journal.pone.0013560
136. Kar P Karna R A review of the diagnosis and management of hepatitis E Curr Treat Options Infect Dis 2020 12 310 20 10.1007/s40506-020-00235-4 32837339
Kar P, Karna R. A review of the diagnosis and management of hepatitis E. Curr Treat Options Infect Dis. 2020;12:310–20.32837339 10.1007/s40506-020-00235-4
137. Lan X Yang B Li BY Yin XP Li XR Liu JX Reverse transcription-loop-mediated isothermal amplification assay for rapid detection of hepatitis E virus J Clin Microbiol 2009 47 7 2304 6 10.1128/JCM.00498-09 19403760
Lan X, Yang B, Li BY, Yin XP, Li XR, Liu JX. Reverse transcription-loop-mediated isothermal amplification assay for rapid detection of hepatitis E virus. J Clin Microbiol. 2009;47(7):2304–6.19403760 10.1128/JCM.00498-09
138. Sauleda S Ong E Bes M Janssen A Cory R Babizki M Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from C atalonia (S pain) Transfusion 2015 55 5 972 9 10.1111/trf.12929 25403913
Sauleda S, Ong E, Bes M, Janssen A, Cory R, Babizki M, et al. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from C atalonia (S pain). Transfusion. 2015;55(5):972–9.25403913 10.1111/trf.12929
139. Abravanel F Chapuy-Regaud S Lhomme S Miedougé M Peron J-M Alric L Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients J Clin Virol 2013 58 4 624 8 10.1016/j.jcv.2013.10.003 24183927
Abravanel F, Chapuy-Regaud S, Lhomme S, Miedougé M, Peron J-M, Alric L, et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. J Clin Virol. 2013;58(4):624–8.24183927 10.1016/j.jcv.2013.10.003
140. Velavan TP Pallerla SR Johne R Todt D Steinmann E Schemmerer M Hepatitis E: an update on one health and clinical medicine Liver Int 2021 41 7 1462 73 10.1111/liv.14912 33960603
Velavan TP, Pallerla SR, Johne R, Todt D, Steinmann E, Schemmerer M, et al. Hepatitis E: an update on one health and clinical medicine. Liver Int. 2021;41(7):1462–73.33960603 10.1111/liv.14912
141. Pischke S Hardtke S Bode U Birkner S Chatzikyrkou C Kauffmann W Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience Liver Int 2013 33 5 722 6 10.1111/liv.12114 23489973
Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int. 2013;33(5):722–6.23489973 10.1111/liv.12114
142. Kamar N Abravanel F Garrouste C Cardeau-Desangles I Mansuy JM Weclawiak H Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient Nephrol Dialysis Transplantation 2010 25 8 2792 5 10.1093/ndt/gfq282
Kamar N, Abravanel F, Garrouste C, Cardeau-Desangles I, Mansuy JM, Weclawiak H, et al. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dialysis Transplantation. 2010;25(8):2792–5.10.1093/ndt/gfq282
143. Kamar N Dalton HR Abravanel F Izopet J Hepatitis E virus infection Clin Microbiol Rev 2014 27 1 116 38 10.1128/CMR.00057-13 24396139
Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27(1):116–38.24396139 10.1128/CMR.00057-13
144. Lhomme S Marion O Abravanel F Izopet J Kamar N Clinical manifestations, Pathogenesis and treatment of Hepatitis E Virus infections J Clin Med 2020 9 2 331 10.3390/jcm9020331 31991629
Lhomme S, Marion O, Abravanel F, Izopet J, Kamar N. Clinical manifestations, Pathogenesis and treatment of Hepatitis E Virus infections. J Clin Med. 2020;9(2):331.31991629 10.3390/jcm9020331
145. Kamar N Rostaing L Abravanel F Garrouste C Esposito L Cardeau-Desangles I Pegylated interferon-α for treating chronic hepatitis E virus infection after liver transplantation Clin Infect Dis 2010 50 5 e30 3 10.1086/650488 20113176
Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, et al. Pegylated interferon-α for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50(5):e30–3.20113176 10.1086/650488
146. Gorris M van Der Lecq BM van Erpecum KJ de Bruijne J Treatment for chronic hepatitis E virus infection: a systematic review and meta-analysis J Viral Hepatitis 2021 28 3 454 63 10.1111/jvh.13456
Gorris M, van Der Lecq BM, van Erpecum KJ, de Bruijne J. Treatment for chronic hepatitis E virus infection: a systematic review and meta-analysis. J Viral Hepatitis. 2021;28(3):454–63.10.1111/jvh.13456
147. Todt D Gisa A Radonic A Nitsche A Behrendt P Suneetha PV In vivo evidence for Ribavirin-induced mutagenesis of the hepatitis E virus genome Gut 2016 65 10 1733 43 10.1136/gutjnl-2015-311000 27222534
Todt D, Gisa A, Radonic A, Nitsche A, Behrendt P, Suneetha PV, et al. In vivo evidence for Ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut. 2016;65(10):1733–43.27222534 10.1136/gutjnl-2015-311000
148. Todt D Meister TL Steinmann E Hepatitis E virus treatment and Ribavirin therapy: viral mechanisms of nonresponse Curr Opin Virol 2018 32 80 7 10.1016/j.coviro.2018.10.001 30384328
Todt D, Meister TL, Steinmann E. Hepatitis E virus treatment and Ribavirin therapy: viral mechanisms of nonresponse. Curr Opin Virol. 2018;32:80–7.30384328 10.1016/j.coviro.2018.10.001
149. Debing Y Ramière C Dallmeier K Piorkowski G Trabaud M-A Lebossé F Hepatitis E virus mutations associated with Ribavirin treatment failure result in altered viral fitness and Ribavirin sensitivity J Hepatol 2016 65 3 499 508 10.1016/j.jhep.2016.05.002 27174035
Debing Y, Ramière C, Dallmeier K, Piorkowski G, Trabaud M-A, Lebossé F, et al. Hepatitis E virus mutations associated with Ribavirin treatment failure result in altered viral fitness and Ribavirin sensitivity. J Hepatol. 2016;65(3):499–508.27174035 10.1016/j.jhep.2016.05.002
150. Wang B Mahsoub HM Li W Heffron CL Tian D Hassebroek AM Ribavirin treatment failure-associated mutation, Y1320H, in the RNA-dependent RNA polymerase of genotype 3 hepatitis E virus (HEV) enhances virus replication in a rabbit HEV infection model Mbio 2023 14 2 e03372 22 10.1128/mbio.03372-22 36809085
Wang B, Mahsoub HM, Li W, Heffron CL, Tian D, Hassebroek AM, et al. Ribavirin treatment failure-associated mutation, Y1320H, in the RNA-dependent RNA polymerase of genotype 3 hepatitis E virus (HEV) enhances virus replication in a rabbit HEV infection model. Mbio. 2023;14(2):e03372–22.36809085 10.1128/mbio.03372-22
151. Lhomme S Kamar N Nicot F Ducos J Bismuth M Garrigue V Mutation in the hepatitis E virus polymerase and outcome of Ribavirin therapy Antimicrob Agents Chemother 2016 60 3 1608 14 10.1128/AAC.02496-15
Lhomme S, Kamar N, Nicot F, Ducos J, Bismuth M, Garrigue V, et al. Mutation in the hepatitis E virus polymerase and outcome of Ribavirin therapy. Antimicrob Agents Chemother. 2016;60(3):1608–14.10.1128/AAC.02496-15
152. Meister TL, Brüggemann Y, Nocke MK, Ulrich RG, Schuhenn J, Sutter K et al. A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function. Proceedings of the National Academy of Sciences. 2022;119(34):e2202653119.
153. Peron J-M Larrue H Izopet J Buti M The pressing need for a global HEV vaccine J Hepatol 2023 79 3 876 80 10.1016/j.jhep.2023.03.024 37003442
Peron J-M, Larrue H, Izopet J, Buti M. The pressing need for a global HEV vaccine. J Hepatol. 2023;79(3):876–80.37003442 10.1016/j.jhep.2023.03.024
154. Safary A Perspectives of vaccination against hepatitis E Intervirology 2001 44 2–3 162 6 10.1159/000050043 11509877
Safary A. Perspectives of vaccination against hepatitis E. Intervirology. 2001;44(2–3):162–6.11509877 10.1159/000050043
155. Shrestha MP Scott RM Joshi DM Mammen MP Jr Thapa GB Thapa N Safety and efficacy of a recombinant hepatitis E vaccine N Engl J Med 2007 356 9 895 903 10.1056/NEJMoa061847 17329696
Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356(9):895–903.17329696 10.1056/NEJMoa061847
156. Cao Y Bing Z Guan S Zhang Z Wang X Development of new hepatitis E vaccines Hum Vaccines Immunotherapeutics 2018 14 9 2254 62 10.1080/21645515.2018.1469591
Cao Y, Bing Z, Guan S, Zhang Z, Wang X. Development of new hepatitis E vaccines. Hum Vaccines Immunotherapeutics. 2018;14(9):2254–62.10.1080/21645515.2018.1469591
157. Zhu F-C Zhang J Zhang X-F Zhou C Wang Z-Z Huang S-J Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial Lancet 2010 376 9744 895 902 10.1016/S0140-6736(10)61030-6 20728932
Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang Z-Z, Huang S-J, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895–902.20728932 10.1016/S0140-6736(10)61030-6
158. Kao CM, Rostad CA, Nolan LE, Peters E, Kleinhenz J, Sherman JD et al. A phase 1, Double-Blinded, placebo-controlled clinical trial to evaluate the safety and immunogenicity of HEV-239 (Hecolin) vaccine in Healthy US adults. J Infect Dis. 2024:jiae148.
159. Sehgal D Malik PS Jameel S Purification and diagnostic utility of a recombinant hepatitis E virus capsid protein expressed in insect larvae Protein Exp Purif 2003 27 1 27 34 10.1016/S1046-5928(02)00574-0
Sehgal D, Malik PS, Jameel S. Purification and diagnostic utility of a recombinant hepatitis E virus capsid protein expressed in insect larvae. Protein Exp Purif. 2003;27(1):27–34.10.1016/S1046-5928(02)00574-0
160. Trabelsi K Kamen A Kallel H Development of a vectored vaccine against hepatitis E virus Vaccine 2014 32 24 2808 11 10.1016/j.vaccine.2014.02.041 24583005
Trabelsi K, Kamen A, Kallel H. Development of a vectored vaccine against hepatitis E virus. Vaccine. 2014;32(24):2808–11.24583005 10.1016/j.vaccine.2014.02.041
161. Dong C Dai X Meng J-H The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E Vaccine 2007 25 9 1662 8 10.1016/j.vaccine.2006.11.001 17156900
Dong C, Dai X, Meng J-H. The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E. Vaccine. 2007;25(9):1662–8.17156900 10.1016/j.vaccine.2006.11.001
162. Innis BL Lynch JA Immunization against hepatitis E Cold Spring Harbor Perspect Med 2018 8 11 a032573 10.1101/cshperspect.a032573
Innis BL, Lynch JA. Immunization against hepatitis E. Cold Spring Harbor Perspect Med. 2018;8(11):a032573.10.1101/cshperspect.a032573
163. Kim J-H Nelson KE Panzner U Kasture Y Labrique AB Wierzba TF A systematic review of the epidemiology of hepatitis E virus in Africa BMC Infect Dis 2014 14 1 1 13 10.1186/1471-2334-14-308 24380631
Kim J-H, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF. A systematic review of the epidemiology of hepatitis E virus in Africa. BMC Infect Dis. 2014;14(1):1–13.24380631 10.1186/1471-2334-14-308
164. Kinast V Burkard TL Todt D Steinmann E Hepatitis E virus drug development Viruses 2019 11 6 485 10.3390/v11060485 31141919
Kinast V, Burkard TL, Todt D, Steinmann E. Hepatitis E virus drug development. Viruses. 2019;11(6):485.31141919 10.3390/v11060485
165. Gabrielli F Alberti F Russo C Cursaro C Seferi H Margotti M Treatment options for hepatitis A and E: a non-systematic review Viruses 2023 15 5 1080 10.3390/v15051080 37243166
Gabrielli F, Alberti F, Russo C, Cursaro C, Seferi H, Margotti M, et al. Treatment options for hepatitis A and E: a non-systematic review. Viruses. 2023;15(5):1080.37243166 10.3390/v15051080
166. Thi VLD Debing Y Wu X Rice CM Neyts J Moradpour D Sofosbuvir inhibits Hepatitis E virus replication in vitro and results in an additive effect when combined with Ribavirin Gastroenterology 2016 150 1 82 5 10.1053/j.gastro.2015.09.011 26408347
Thi VLD, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, et al. Sofosbuvir inhibits Hepatitis E virus replication in vitro and results in an additive effect when combined with Ribavirin. Gastroenterology. 2016;150(1):82–5. e4.26408347 10.1053/j.gastro.2015.09.011
167. Cornberg M Pischke S Müller T Behrendt P Piecha F Benckert J Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E–the HepNet SofE pilot study J Hepatol 2020 73 3 696 9 10.1016/j.jhep.2020.05.020 32624195
Cornberg M, Pischke S, Müller T, Behrendt P, Piecha F, Benckert J, et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E–the HepNet SofE pilot study. J Hepatol. 2020;73(3):696–9.32624195 10.1016/j.jhep.2020.05.020
168. Gömer A Klöhn M Jagst M Nocke MK Pischke S Horvatits T Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients Hepatology 2023 78 6 1882 95 37334496
Gömer A, Klöhn M, Jagst M, Nocke MK, Pischke S, Horvatits T, et al. Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients. Hepatology. 2023;78(6):1882–95.37334496
169. Guo H Liu D Liu K Hou Y Li C Li Q Drug repurposing screen identifies vidofludimus calcium and pyrazofurin as novel chemical entities for the development of hepatitis E interventions Virol Sin 2024 39 1 123 33 10.1016/j.virs.2023.11.006 37984761
Guo H, Liu D, Liu K, Hou Y, Li C, Li Q, et al. Drug repurposing screen identifies vidofludimus calcium and pyrazofurin as novel chemical entities for the development of hepatitis E interventions. Virol Sin. 2024;39(1):123–33.37984761 10.1016/j.virs.2023.11.006
170. Qu C Xu L Yin Y Peppelenbosch MP Pan Q Wang W Nucleoside analogue 2’-C-methylcytidine inhibits hepatitis E virus replication but antagonizes Ribavirin Arch Virol 2017 162 2989 96 10.1007/s00705-017-3444-8 28623406
Qu C, Xu L, Yin Y, Peppelenbosch MP, Pan Q, Wang W. Nucleoside analogue 2’-C-methylcytidine inhibits hepatitis E virus replication but antagonizes Ribavirin. Arch Virol. 2017;162:2989–96.28623406 10.1007/s00705-017-3444-8
171. Jagst M, Gömer A, Todt D, Steinmann E. Performance of sofosbuvir and NITD008 in extrahepatic neuronal cells against HEV. Antiviral Res. 2024:105922.
172. Hooda P Al-Dosari M Sinha N Parvez MK Sehgal D Inhibition of HEV replication by FDA-Approved RdRp inhibitors ACS Omega 2023 8 44 41570 8 10.1021/acsomega.3c05637 37969986
Hooda P, Al-Dosari M, Sinha N, Parvez MK, Sehgal D. Inhibition of HEV replication by FDA-Approved RdRp inhibitors. ACS Omega. 2023;8(44):41570–8.37969986 10.1021/acsomega.3c05637
173. Dalton HR Bendall R Ijaz S Banks M Hepatitis E: an emerging infection in developed countries Lancet Infect Dis 2008 8 11 698 709 10.1016/S1473-3099(08)70255-X 18992406
Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8(11):698–709.18992406 10.1016/S1473-3099(08)70255-X
174. Khuroo MS Khuroo MS Hepatitis E: an emerging global disease–from discovery towards control and cure J Viral Hepatitis 2016 23 2 68 79 10.1111/jvh.12445
Khuroo MS, Khuroo MS. Hepatitis E: an emerging global disease–from discovery towards control and cure. J Viral Hepatitis. 2016;23(2):68–79.10.1111/jvh.12445
175. Guthmann J-P Klovstad H Boccia D Hamid N Pinoges L Nizou J-Y A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods Clin Infect Dis 2006 42 12 1685 91 10.1086/504321 16705572
Guthmann J-P, Klovstad H, Boccia D, Hamid N, Pinoges L, Nizou J-Y, et al. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis. 2006;42(12):1685–91.16705572 10.1086/504321
176. Labrique AB Thomas DL Stoszek SK Nelson KE Hepatitis E: an emerging infectious disease Epidemiol Rev 1999 21 2 162 79 10.1093/oxfordjournals.epirev.a017994 10682255
Labrique AB, Thomas DL, Stoszek SK, Nelson KE. Hepatitis E: an emerging infectious disease. Epidemiol Rev. 1999;21(2):162–79.10682255 10.1093/oxfordjournals.epirev.a017994
177. Balayan M Andjaparidze A Savinskaya S Ketiladze E Braginsky D Savinov A Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route Intervirology 1983 20 1 23 31 10.1159/000149370 6409836
Balayan M, Andjaparidze A, Savinskaya S, Ketiladze E, Braginsky D, Savinov A, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20(1):23–31.6409836 10.1159/000149370
178. Zhao C Ma Z Harrison TJ Feng R Zhang C Qiao Z A novel genotype of hepatitis E virus prevalent among farmed rabbits in China J Med Virol 2009 81 8 1371 9 10.1002/jmv.21536 19551838
Zhao C, Ma Z, Harrison TJ, Feng R, Zhang C, Qiao Z, et al. A novel genotype of hepatitis E virus prevalent among farmed rabbits in China. J Med Virol. 2009;81(8):1371–9.19551838 10.1002/jmv.21536
179. Woo PC Lau SK Teng JL Tsang AK Joseph M Wong EY New Hepatitis E virus genotype in camels, the Middle East Emerg Infect Dis 2014 20 6 1044 10.3201/eid2006.140140 24856611
Woo PC, Lau SK, Teng JL, Tsang AK, Joseph M, Wong EY, et al. New Hepatitis E virus genotype in camels, the Middle East. Emerg Infect Dis. 2014;20(6):1044.24856611 10.3201/eid2006.140140
180. Drexler JF Seelen A Corman VM Fumie Tateno A Cottontail V Melim Zerbinati R Bats worldwide carry hepatitis E virus-related viruses that form a putative novel genus within the family Hepeviridae J Virol 2012 86 17 9134 47 10.1128/JVI.00800-12 22696648
Drexler JF, Seelen A, Corman VM, Fumie Tateno A, Cottontail V, Melim Zerbinati R, et al. Bats worldwide carry hepatitis E virus-related viruses that form a putative novel genus within the family Hepeviridae. J Virol. 2012;86(17):9134–47.22696648 10.1128/JVI.00800-12
181. Batts W Yun S Hedrick R Winton J A novel member of the family Hepeviridae from cutthroat trout (Oncorhynchus clarkii) Virus Res 2011 158 1–2 116 23 10.1016/j.virusres.2011.03.019 21458509
Batts W, Yun S, Hedrick R, Winton J. A novel member of the family Hepeviridae from cutthroat trout (Oncorhynchus clarkii). Virus Res. 2011;158(1–2):116–23.21458509 10.1016/j.virusres.2011.03.019
182. Takahashi M Tanaka T Takahashi H Hoshino Y Nagashima S Jirintai f Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation J Clin Microbiol 2010 48 4 1112 25 10.1128/JCM.02002-09 20107086
Takahashi M, Tanaka T, Takahashi H, Hoshino Y, Nagashima S, Jirintai f, et al. Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J Clin Microbiol. 2010;48(4):1112–25.20107086 10.1128/JCM.02002-09
183. Johne R Plenge-Bonig A Hess M Ulrich RG Reetz J Schielke A Detection of a novel hepatitis E-like virus in faeces of wild rats using a nested broad-spectrum RT-PCR J Gen Virol 2010 91 3 750 8 10.1099/vir.0.016584-0 19889929
Johne R, Plenge-Bonig A, Hess M, Ulrich RG, Reetz J, Schielke A. Detection of a novel hepatitis E-like virus in faeces of wild rats using a nested broad-spectrum RT-PCR. J Gen Virol. 2010;91(3):750–8.19889929 10.1099/vir.0.016584-0
184. Meng X-J, Purcell RH, Halbur PG, Lehman JR, Webb DM, Tsareva TS et al. A novel virus in swine is closely related to the human hepatitis E virus. Proceedings of the National Academy of Sciences. 1997;94(18):9860-5.
185. Koonin EV, Gorbalenya AE, Purdy MA, Rozanov MN, Reyes GR, Bradley DW. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proceedings of the National Academy of Sciences. 1992;89(17):8259-63.
186. Karpe YA, Lole KS. Deubiquitination activity associated with hepatitis E virus putative papain-like cysteine protease. Microbiology Society; 2011.
187. Karpe YA Lole KS RNA 5′-triphosphatase activity of the hepatitis E virus helicase domain J Virol 2010 84 18 9637 41 10.1128/JVI.00492-10 20592074
Karpe YA, Lole KS. RNA 5′-triphosphatase activity of the hepatitis E virus helicase domain. J Virol. 2010;84(18):9637–41.20592074 10.1128/JVI.00492-10
188. Agrawal S Gupta D Panda SK The 3′ end of hepatitis E virus (HEV) genome binds specifically to the viral RNA-dependent RNA polymerase (RdRp) Virology 2001 282 1 87 101 10.1006/viro.2000.0819 11259193
Agrawal S, Gupta D, Panda SK. The 3′ end of hepatitis E virus (HEV) genome binds specifically to the viral RNA-dependent RNA polymerase (RdRp). Virology. 2001;282(1):87–101.11259193 10.1006/viro.2000.0819
189. Jameel S Zafrullah M Ozdener MH Panda SK Expression in animal cells and characterization of the hepatitis E virus structural proteins J Virol 1996 70 1 207 16 10.1128/jvi.70.1.207-216.1996 8523527
Jameel S, Zafrullah M, Ozdener MH, Panda SK. Expression in animal cells and characterization of the hepatitis E virus structural proteins. J Virol. 1996;70(1):207–16.8523527 10.1128/jvi.70.1.207-216.1996
190. Torresi J Li F Locarnini SA Anderson DA Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells J Gen Virol 1999 80 5 1185 8 10.1099/0022-1317-80-5-1185 10355765
Torresi J, Li F, Locarnini SA, Anderson DA. Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells. J Gen Virol. 1999;80(5):1185–8.10355765 10.1099/0022-1317-80-5-1185
191. Zhou Y-H Purcell RH Emerson SU A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus Vaccine 2005 23 24 3157 65 10.1016/j.vaccine.2004.12.020 15837215
Zhou Y-H, Purcell RH, Emerson SU. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine. 2005;23(24):3157–65.15837215 10.1016/j.vaccine.2004.12.020
192. Nagashima S Takahashi M Jirintai n Tanaka T Yamada K Nishizawa T A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells J Gen Virol 2011 92 2 269 78 10.1099/vir.0.025791-0 21068219
Nagashima S, Takahashi M, Jirintai n, Tanaka T, Yamada K, Nishizawa T, et al. A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells. J Gen Virol. 2011;92(2):269–78.21068219 10.1099/vir.0.025791-0
193. Nagashima S Takahashi M Jirintai S Tanaka T Nishizawa T Yasuda J Tumour susceptibility gene 101 and the vacuolar protein sorting pathway are required for the release of hepatitis E virions J Gen Virol 2011 92 12 2838 48 10.1099/vir.0.035378-0 21880841
Nagashima S, Takahashi M, Jirintai S, Tanaka T, Nishizawa T, Yasuda J, et al. Tumour susceptibility gene 101 and the vacuolar protein sorting pathway are required for the release of hepatitis E virions. J Gen Virol. 2011;92(12):2838–48.21880841 10.1099/vir.0.035378-0
194. Nagashima S Jirintai S Takahashi M Kobayashi T Tanggis, Nishizawa T Hepatitis E virus egress depends on the exosomal pathway, with secretory exosomes derived from multivesicular bodies J Gen Virol 2014 95 10 2166 75 10.1099/vir.0.066910-0 24970738
Nagashima S, Jirintai S, Takahashi M, Kobayashi T, Tanggis, Nishizawa T, et al. Hepatitis E virus egress depends on the exosomal pathway, with secretory exosomes derived from multivesicular bodies. J Gen Virol. 2014;95(10):2166–75.24970738 10.1099/vir.0.066910-0
195. Dalton HR van Eijk JJ Cintas P Madden RG Jones C Webb GW Hepatitis E virus infection and acute non-traumatic neurological injury: a prospective multicentre study J Hepatol 2017 67 5 925 32 10.1016/j.jhep.2017.07.010 28734938
Dalton HR, van Eijk JJ, Cintas P, Madden RG, Jones C, Webb GW, et al. Hepatitis E virus infection and acute non-traumatic neurological injury: a prospective multicentre study. J Hepatol. 2017;67(5):925–32.28734938 10.1016/j.jhep.2017.07.010
196. Van Eijk JJ Dalton HR Ripellino P Madden RG Jones C Fritz M Clinical phenotype and outcome of hepatitis E virus–associated neuralgic amyotrophy Neurology 2017 89 9 909 17 10.1212/WNL.0000000000004297 28768846
Van Eijk JJ, Dalton HR, Ripellino P, Madden RG, Jones C, Fritz M, et al. Clinical phenotype and outcome of hepatitis E virus–associated neuralgic amyotrophy. Neurology. 2017;89(9):909–17.28768846 10.1212/WNL.0000000000004297
197. van den Berg B van der Eijk AA Pas SD Hunter JG Madden RG Tio-Gillen AP Guillain-Barré syndrome associated with preceding hepatitis E virus infection Neurology 2014 82 6 491 7 10.1212/WNL.0000000000000111 24415572
van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology. 2014;82(6):491–7.24415572 10.1212/WNL.0000000000000111
198. Perrin HB Cintas P Abravanel F Gerolami R d’Alteroche L Raynal J-N Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E Emerg Infect Dis 2015 21 11 1928 10.3201/eid2111.141789 26490255
Perrin HB, Cintas P, Abravanel F, Gerolami R, d’Alteroche L, Raynal J-N, et al. Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E. Emerg Infect Dis. 2015;21(11):1928.26490255 10.3201/eid2111.141789
199. Wang Y Wang S Wu J Jiang Y Zhang H Li S Hepatitis E virus infection in acute non-traumatic neuropathy: a large prospective case-control study in China EBioMedicine 2018 36 122 30 10.1016/j.ebiom.2018.08.053 30190208
Wang Y, Wang S, Wu J, Jiang Y, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: a large prospective case-control study in China. EBioMedicine. 2018;36:122–30.30190208 10.1016/j.ebiom.2018.08.053
200. Mengel AM Stenzel W Meisel A Büning C Hepatitis E–induced severe myositis Muscle Nerve 2016 53 2 317 20 10.1002/mus.24959 26514272
Mengel AM, Stenzel W, Meisel A, Büning C. Hepatitis E–induced severe myositis. Muscle Nerve. 2016;53(2):317–20.26514272 10.1002/mus.24959
201. Marion O Abravanel F Del Bello A Esposito L Lhomme S Puissant-Lubrano B Hepatitis E virus–associated cryoglobulinemia in solid‐organ–transplant recipients Liver Int 2018 38 12 2178 89 10.1111/liv.13894 29845733
Marion O, Abravanel F, Del Bello A, Esposito L, Lhomme S, Puissant-Lubrano B, et al. Hepatitis E virus–associated cryoglobulinemia in solid‐organ–transplant recipients. Liver Int. 2018;38(12):2178–89.29845733 10.1111/liv.13894
202. Premkumar M, Rangegowda D, Vashishtha C, Bhatia V, Khumuckham JS, Kumar B. Acute viral hepatitis E is associated with the development of myocarditis. Case Rep Hepatol. 2015;2015.
203. Kishore J Sen M Parvovirus B19-induced thrombocytopenia and anemia in a child with fatal fulminant hepatic failure coinfected with hepatitis A and E viruses J Trop Pediatr 2009 55 5 335 7 10.1093/tropej/fmp004 19203989
Kishore J, Sen M. Parvovirus B19-induced thrombocytopenia and anemia in a child with fatal fulminant hepatic failure coinfected with hepatitis A and E viruses. J Trop Pediatr. 2009;55(5):335–7.19203989 10.1093/tropej/fmp004
204. Peter J, Stallmach A, Tannapfel A, Bruns T. Acute-on-chronic liver failure with complicating Pancreatitis after Autochthonous Hepatitis E infection. Hepat Monthly. 2017;17(11).
205. Thakur A Basu PP Acute non-fulminant viral Hepatitis E presenting with acute pancreatitis—an unusual presentation Malaysian J Med Sciences: MJMS 2017 24 4 102 10.21315/mjms2017.24.4.12
Thakur A, Basu PP. Acute non-fulminant viral Hepatitis E presenting with acute pancreatitis—an unusual presentation. Malaysian J Med Sciences: MJMS. 2017;24(4):102.10.21315/mjms2017.24.4.12
206. Dumoulin FL Liese H Acute hepatitis E virus infection and autoimmune thyroiditis: yet another trigger? Case Rep 2012 2012 bcr1220115441
Dumoulin FL, Liese H. Acute hepatitis E virus infection and autoimmune thyroiditis: yet another trigger? Case Rep. 2012;2012:bcr1220115441.
207. Del Bello A Guilbeau-Frugier C Josse AG Rostaing L Izopet J Kamar N Successful treatment of hepatitis E virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis with Ribavirin Transpl Infect Disease 2015 17 2 279 83 10.1111/tid.12353 25708383
Del Bello A, Guilbeau-Frugier C, Josse AG, Rostaing L, Izopet J, Kamar N. Successful treatment of hepatitis E virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis with Ribavirin. Transpl Infect Disease. 2015;17(2):279–83.25708383 10.1111/tid.12353
208. Guinault D Ribes D Delas A Milongo D Abravanel F Puissant-Lubrano B Hepatitis E virus–induced cryoglobulinemic glomerulonephritis in a nonimmunocompromised person Am J Kidney Dis 2016 67 4 660 3 10.1053/j.ajkd.2015.10.022 26682764
Guinault D, Ribes D, Delas A, Milongo D, Abravanel F, Puissant-Lubrano B, et al. Hepatitis E virus–induced cryoglobulinemic glomerulonephritis in a nonimmunocompromised person. Am J Kidney Dis. 2016;67(4):660–3.26682764 10.1053/j.ajkd.2015.10.022
